AZD8055

Name: AZD8055
Brand: Selleck Chemicals
SKU: S1555
Rating: 5 (167 reviews)

For research use only.

Catalog No.S1555

167 publications

CAS No. 1009298-09-2

AZD8055 is a novel ATP-competitive mTOR inhibitor with IC50 of 0.8 nM in MDA-MB-468 cells with excellent selectivity (∼1,000-fold) against PI3K isoforms and ATM/DNA-PK. AZD8055 induces caspase-dependent apoptosis and also induces autophagy. Phase 1.

Selleck's AZD8055 has been cited by 167 publications

Nature, 2019, 10.1038/s41586-019-1607-3

PubMed: 31578521 ( click the link to review the publication )

Nat Med, 2019, 25(5):838-849

PubMed: 31011202 ( click the link to review the publication )

Cancer Cell, 2019, 35(5):752-766

PubMed: 31085176 ( click the link to review the publication )

Cell, 2018, 172(1-2):373-386

PubMed: 29224780 ( click the link to review the publication )

Cell Stem Cell, 2018, 22(3):369-383

PubMed: 29499153 ( click the link to review the publication )

Nat Med, 2017, 23(2):200-212

PubMed: 28067899 ( click the link to review the publication )

Cell Stem Cell, 2017, 20(2):177-190

PubMed: 27939219 ( click the link to review the publication )

Cancer Cell, 2017, 31(5):635-652

PubMed: 28434841 ( click the link to review the publication )

Nat Med, 2015, 10.1038/nm.3855

PubMed: 25939062 ( click the link to review the publication )

Cancer Discov, 2015, 5(3):255-63

PubMed: 25564516 ( click the link to review the publication )

Cancer Discov, 2015, 5(3):245-54

PubMed: 25564517 ( click the link to review the publication )

Cancer Cell, 2015, 27(1):97-108

PubMed: 25544637 ( click the link to review the publication )

Cancer Cell, 2015, 27(4):533-46

PubMed: 25873175 ( click the link to review the publication )

Nat Commun, 2020, 11(1):4684

PubMed: 32943635 ( click the link to review the publication )

Clin Cancer Res, 2020, 10.1158/1078-0432

PubMed: 32034078 ( click the link to review the publication )

Cell Rep, 2020, 31(12):107810

PubMed: 32579936 ( click the link to review the publication )

Eur J Cancer, 2020, 126:93-103

PubMed: 31927215 ( click the link to review the publication )

J Bone Miner Res, 2020, 10.1002/jbmr.4176

PubMed: 32916025 ( click the link to review the publication )

J Exp Clin Cancer Res, 2020, 9;39(1):107

PubMed: 32517736 ( click the link to review the publication )

Br J Cancer, 2020, 22

PubMed: 32439932 ( click the link to review the publication )

Front Immunol, 2020, 11:572960

PubMed: 33013932 ( click the link to review the publication )

Mol Cancer Ther, 2020, 5;molcanther.1131.2019

PubMed: 32371585 ( click the link to review the publication )

Mol Cancer Ther, 2020, 19(3):882-894

PubMed: 31879363 ( click the link to review the publication )

J Cancer, 2020, 15;11(12):3492-3501

PubMed: 32284745 ( click the link to review the publication )
Sci Rep, 2020, 4;10(1):4025

PubMed: 32132574 ( click the link to review the publication )

J Biol Chem, 2020, 22;295(21):7418-7430

PubMed: 32312748 ( click the link to review the publication )

Biosci Rep, 2020, 30;40(4):BSR20200905

PubMed: 32285908 ( click the link to review the publication )

Biochem Biophys Res Commun, 2020, 23;S0006-291X(20)30951-7

PubMed: 32456793 ( click the link to review the publication )

G3 (Bethesda), 2020, 4;10(5):1585-1597

PubMed: 32265286 ( click the link to review the publication )

Nat Commun, 2020, 11(1):3627

PubMed: 32686664 ( click the link to review the publication )

BMC Cancer, 2020, 20(1):724

PubMed: 32758183 ( click the link to review the publication )

Nat Med, 2020, 10.1038/s41591-020-0986-1

PubMed: 32719489 ( click the link to review the publication )

J Cell Biol, 2020, 219(2)

PubMed: 31914171 ( click the link to review the publication )

J Invest Dermatol, 2020, S0022-202X(20)31981-3

PubMed: 32805217 ( click the link to review the publication )

Int Immunopharmacol, 2020, 81:106241

PubMed: 32058927 ( click the link to review the publication )

Cell Rep, 2020, 32(3):107933

PubMed: 32697996 ( click the link to review the publication )

Mol Oncol, 2020, 10.1002/1878-0261.12673

PubMed: 32191822 ( click the link to review the publication )

Cancer, 2020, 10.1002/cncr.33071

PubMed: 32767682 ( click the link to review the publication )

Mol Cell, 2019, 10.1016/j.molcel.2019.10.016

PubMed: 31733992 ( click the link to review the publication )

Autophagy, 2019, 10.1080/15548627.2019.1660545

PubMed: 31462148 ( click the link to review the publication )

Autophagy, 2019, 15(3):543-557

PubMed: 30269645 ( click the link to review the publication )

Clin Cancer Res, 2019, 25(21):6429-6442

PubMed: 31439581 ( click the link to review the publication )

Clin Cancer Res, 2019, 25(16):5107-5121

PubMed: 31164374 ( click the link to review the publication )

Curr Biol, 2019, 29(5):737-749

PubMed: 30773367 ( click the link to review the publication )

Cell Rep, 2019, 27(12):3696-3708.e5

PubMed: 31216485 ( click the link to review the publication )

Sci Signal, 2019, 12(612)

PubMed: 31848319 ( click the link to review the publication )

Cancers (Basel), 2019, 11(10)

PubMed: 31627299 ( click the link to review the publication )

Cell Chem Biol, 2019, 26(3):366-377

PubMed: 30661989 ( click the link to review the publication )
Am J Cancer Res, 2019, 9(9):1922-1937

PubMed: 31598395 ( click the link to review the publication )

Sci Rep, 2019, 9(1):30

PubMed: 30631106 ( click the link to review the publication )

Sci Rep, 2019, 9(1):9805

PubMed: 31285446 ( click the link to review the publication )

Cancer Gene Ther, 2019, 10.1038/s41417-019-0117-7

PubMed: 31257364 ( click the link to review the publication )

Biochem J, 2019, 476(20):3081-3107

PubMed: 31665227 ( click the link to review the publication )

Front Physiol, 2019, 10:167

PubMed: 30873046 ( click the link to review the publication )

Biomed Res Int, 2019, 2019:5196028

PubMed: 31223619 ( click the link to review the publication )

Cell Mol Gastroenterol Hepatol, 2019, 8(1):21-36

PubMed: 30831322 ( click the link to review the publication )

Cancer Biol Med, 2019, 16(1):66-83

PubMed: 31119047 ( click the link to review the publication )

Nat Cell Biol, 2018, 20(4):465-478

PubMed: 29593330 ( click the link to review the publication )

Cancer Res, 2018, 78(12):3176-3189

PubMed: 29661831 ( click the link to review the publication )

Cancer Res, 2018, 78(15):4396-4410

PubMed: 29844118 ( click the link to review the publication )

Cell Death Dis, 2018, 9(11):1063

PubMed: 30337536 ( click the link to review the publication )

J Mol Cell Biol, 2018, 10(4):331-340

PubMed: 29190376 ( click the link to review the publication )

Acta Pharmacol Sin, 2018, 39(8):1338-1346

PubMed: 29345254 ( click the link to review the publication )

Front Genet, 2018, 9:690

PubMed: 30671083 ( click the link to review the publication )

Cell Signal, 2018, 44:127-137

PubMed: 29329780 ( click the link to review the publication )

PLoS One, 2018, 13(8):e0200725

PubMed: 30067771 ( click the link to review the publication )

Med Sci Monit, 2018, 24:2735-2743

PubMed: 29720580 ( click the link to review the publication )

Oncol Lett, 2018, 16(4):4561-4566

PubMed: 30214591 ( click the link to review the publication )

J Exp Med, 2018, 215(1):159-175

PubMed: 29141866 ( click the link to review the publication )

Oncol Lett, 2018, 16(1):632-642

PubMed: 29928450 ( click the link to review the publication )

Nat Commun, 2017, 8(1):1090

PubMed: 29061961 ( click the link to review the publication )

Nat Commun, 2017, 8(1):2207

PubMed: 29263324 ( click the link to review the publication )
Nucleic Acids Res, 2017, 45(16):9654-9678

PubMed: 28934469 ( click the link to review the publication )

Cell Syst, 2017,

PubMed: 28017544 ( click the link to review the publication )

Mol Syst Biol, 2017, 13(1):905

PubMed: 28069687 ( click the link to review the publication )

Cell Rep, 2017, 20(10):2341-2356

PubMed: 28877469 ( click the link to review the publication )

Oncogene, 2017, 36(15):2074-2084

PubMed: 27748760 ( click the link to review the publication )

Oncogene, 2017, 36(26):3651-3660

PubMed: 28192408 ( click the link to review the publication )

PLoS Pathog, 2017, 13(4):e1006344

PubMed: 28414774 ( click the link to review the publication )

Cell Commun Signal, 2017, 10.1186/s12964-017-0164-3

PubMed: 28143584 ( click the link to review the publication )

Biochim Biophys Acta Mol Cell Res, 2017, 1864(10):1554-1565

PubMed: 28641977 ( click the link to review the publication )

PLoS One, 2017, 12(7):e0181243

PubMed: 28704514 ( click the link to review the publication )

Anticancer Res, 2017, 37(3):1083-1090

PubMed: 28314268 ( click the link to review the publication )

Oncotarget, 2017, 8(4):5992-6002

PubMed: 27863413 ( click the link to review the publication )

Oncotarget, 2017, 8(1):979-987

PubMed: 27894090 ( click the link to review the publication )

Oncotarget, 2017, 8(25):41422-41431

PubMed: 28507282 ( click the link to review the publication )

Nat Cell Biol, 2016, 18(5):527-39

PubMed: 27043084 ( click the link to review the publication )

Genome Biol, 2016, 17(1):149

PubMed: 27380875 ( click the link to review the publication )

Nat Chem Biol, 2016, 12(1):22-8

PubMed: 26595461 ( click the link to review the publication )

EMBO J, 2016, 35(17):1902-22

PubMed: 27481935 ( click the link to review the publication )

Mol Oncol, 2016, 10(1):101-12

PubMed: 26471831 ( click the link to review the publication )

Mol Oncol, 2016, 10(4):538-52

PubMed: 26686971 ( click the link to review the publication )

Aging (Albany NY), 2016, 8(2):231-44

PubMed: 26851731 ( click the link to review the publication )

Aging (Albany NY), 2016, 8(12):3535-3551

PubMed: 28077803 ( click the link to review the publication )

Sci Rep, 2016,

PubMed: 27849011 ( click the link to review the publication )

J Biol Chem, 2016, 291(12):6262-71

PubMed: 26755732 ( click the link to review the publication )
Front Plant Sci, 2016, 7:1746

PubMed: 27917191 ( click the link to review the publication )

Cell Signal, 2016, 28(4):284-93

PubMed: 26795954 ( click the link to review the publication )

PLoS One, 2016, 11(4):e0154564

PubMed: 27128484 ( click the link to review the publication )

Biochem Biophys Res Commun, 2016, 478(4):1515-20

PubMed: 27565731 ( click the link to review the publication )

Int J Endocrinol, 2016, 2016:5286972

PubMed: 27990160 ( click the link to review the publication )

Oncotarget, 2016, 7(44):71211-71222

PubMed: 27655717 ( click the link to review the publication )

Oncotarget, 2016, 7(4):3947-65

PubMed: 26678033 ( click the link to review the publication )

Autophagy, 2015, 11(2):285-97

PubMed: 25801301 ( click the link to review the publication )

Cancer Res, 2015, 75(20):4398-406

PubMed: 26359452 ( click the link to review the publication )

Cell Rep, 2015, 11(3):446-59

PubMed: 25865887 ( click the link to review the publication )

J Hematol Oncol, 2015,

PubMed: 26515759 ( click the link to review the publication )

Sci Signal, 2015, 8(375):ra42

PubMed: 25943352 ( click the link to review the publication )

J Med Chem, 2015, 58(16):6559-73

PubMed: 26237138 ( click the link to review the publication )

Clin Sci, 2015, 128(8):517-26

PubMed: ( click the link to review the publication )

J Cancer, 2015, 6(12):1195-205

PubMed: 26535060 ( click the link to review the publication )

Mol Cancer Res, 2015, 13(2):223-30

PubMed: ( click the link to review the publication )

Mol Cancer Res, 2015, 13(1):120-9

PubMed: ( click the link to review the publication )

Mol Cancer Res, 2015, 13(1):120-9

PubMed: 25232030 ( click the link to review the publication )

Mol Cancer Res, 2015, 13(2):223-30

PubMed: 25582703 ( click the link to review the publication )

J Biol Chem, 2015, 10.1074/jbc.C114.627778

PubMed: 25833948 ( click the link to review the publication )

Biochem J, 2015, 465(2):227-38

PubMed: 25353634 ( click the link to review the publication )

J Chromatogr A, 2015, 1388:267-73

PubMed: 25725958 ( click the link to review the publication )

J Chromatogr A, 2015, 1388:267-73

PubMed: ( click the link to review the publication )

Proteomics, 2015, 10.1002/pmic.201400586

PubMed: 25764225 ( click the link to review the publication )
Cancer Biol Ther, 2015,

PubMed: 25692408 ( click the link to review the publication )

PLoS One, 2015, 10(11):e0143357

PubMed: 26580203 ( click the link to review the publication )

PLoS One, 2015, 10(7):e0131400

PubMed: 26148118 ( click the link to review the publication )

Clin Sci (Lond), 2015, 128(8):517-26

PubMed: 25428582 ( click the link to review the publication )

Oncotarget, 2015, 6(7):5118-33

PubMed: 25742786 ( click the link to review the publication )

Cell Signal, 2015, 27(11):2191-200

PubMed: 26210887 ( click the link to review the publication )

J Clin Invest, 2014, 10.1172/JCI73935

PubMed: 25415435 ( click the link to review the publication )

Nat Commun, 2014, 5:3384

PubMed: 24594970 ( click the link to review the publication )

Autophagy, 2014, 10(6):1120-36

PubMed: 24879157 ( click the link to review the publication )

Leukemia, 2014, 28(5):1092-102

PubMed: 24135829 ( click the link to review the publication )

Cancer Res, 2014, 74(10):2846-56

PubMed: 24614082 ( click the link to review the publication )

Cancer Res, 2014, 74(14):3947-58

PubMed: 24986516 ( click the link to review the publication )

Clin Cancer Res, 2014, 20(22):5756-67

PubMed: 25316808 ( click the link to review the publication )

Int J Cancer, 2014, 10.1002/ijc.28880

PubMed: 24706460 ( click the link to review the publication )

Antioxid Redox Sign, 2014, 20(9):1382-95

PubMed: 24063548 ( click the link to review the publication )

Mol Cell Proteomics, 2014, 13(6):1429-38

PubMed: 24643969 ( click the link to review the publication )

Am J Cancer Res, 2014,

PubMed: 25520871 ( click the link to review the publication )

Am J Cancer Res, 2014, 4(6):824-837

PubMed: ( click the link to review the publication )

Mol Cell Biol, 2014, 34(22):4088-103

PubMed: 25182533 ( click the link to review the publication )

Mol Cell Biol, 2014, 34(13):2517-32

PubMed: 24777602 ( click the link to review the publication )

Mol Reprod Dev, 2014, 81(7):655-65

PubMed: 24753052 ( click the link to review the publication )

Oncol Rep, 2014, 31(2):649-56

PubMed: 24297300 ( click the link to review the publication )

PLoS One, 2014, 9(12):e113555

PubMed: 25460003 ( click the link to review the publication )

Oncotarget, 2014,

PubMed: 25277205 ( click the link to review the publication )
Oncotarget, 2014, 5(21):10732-44

PubMed: 25313141 ( click the link to review the publication )

Oncotarget, 2014, 5(21):10503-17

PubMed: 25361177 ( click the link to review the publication )

Oncotarget, 2014, 5(15):6015-27

PubMed: 24970798 ( click the link to review the publication )

Oncotarget, 2014, 5(18):8737-49

PubMed: 25228590 ( click the link to review the publication )

Blood, 2013, 121(18):3619-30

PubMed: 23444404 ( click the link to review the publication )

EMBO J, 2013, 28;32(17):2377-91

PubMed: 23921550 ( click the link to review the publication )

Cancer Res, 2013, 73(11):3402-11

PubMed: 23585456 ( click the link to review the publication )

Am J Transplant, 2013, 13(8):2035-43

PubMed: 23841834 ( click the link to review the publication )

Sci Signal, 2013, 6(271):ra25

PubMed: 23592840 ( click the link to review the publication )

Mol Cancer Ther, 2013, 13(1):37-48

PubMed: 24233399 ( click the link to review the publication )

Mol Cancer Ther, 2013,

PubMed: 23615631 ( click the link to review the publication )

Mol Oncol, 2013, 33:404-18

PubMed: 24444656 ( click the link to review the publication )

J Hypertens, 2013, 31(2):303-11

PubMed: 23303355 ( click the link to review the publication )

J Biol Chem, 2013, 288(49):35287-96

PubMed: 24133218 ( click the link to review the publication )

Mol Biol Cell, 2013, 24(23):3736-45

PubMed: 24088573 ( click the link to review the publication )

Cancer Chemother Pharmacol, 2013, 71(5):1297-307

PubMed: 23479136 ( click the link to review the publication )

PLoS One, 2013, 8(2):e56567

PubMed: 23451056 ( click the link to review the publication )

Onco Targets Ther, 2013, 6:1373-84

PubMed: 24124380 ( click the link to review the publication )

Biochem Biophys Res Commun, 2013, 440(4):701-6

PubMed: 24103749 ( click the link to review the publication )

Oncol Lett, 2013, 5(2):717-721

PubMed: 23420667 ( click the link to review the publication )

Autophagy, 2012, 9(1):74-92

PubMed: 23196898 ( click the link to review the publication )

Exp Neurol, 2012, 233(2):799-806

PubMed: 22177999 ( click the link to review the publication )

Biochem Pharmacol, 2012, 83(9):1183-94

PubMed: 22305748 ( click the link to review the publication )

Purity & Quality Control

Choose Selective mTOR Inhibitors

Biological Activity

Description

Features

First drug to inhibit both types of mTOR protein.

Targets

mTOR (truncated) ^[1] (MDA-MB-468 cells)	mTOR (full length) ^[1] (MDA-MB-468 cells)
0.13 nM	0.8 nM

In vitro

AZD8055 shows low activity (∼1,000-fold) against all PI3K isoforms (α, β, γ, δ) and other members of the PI3K-like kinase family (ATM and DNA-PK). AZD8055 inhibits the phosphorylation of mTORC1 (p70S6K and 4E-BP1) as well as phosphorylation of the mTORC2 (Akt) and downstream proteins. The rapamycin-resistant T37/46 phosphorylation sites on 4E-BP1 can be fully inhibited by AZD8055, resulting in significant inhibition of cap-dependent translation. AZD8055 potently inhibits proliferation in U87MG, A549 and H838 cells with IC50 of 53, 50 and 20 nM, respectively. AZD8055 also induces autophagy and increased LC3-II levels in H838 and A549 cells. ^[1] AZD8055 decreases AML blast cell proliferation and cell cycle progression, reduces the clonogenic growth of leukemic progenitors and induces caspase-dependent apoptosis in leukemic cells but not in normal immature CD34+ cells. ^[2] AZD8055 indicates inhibitory against the pediatric preclinical testing program (PPTP) cell lines with IC50 of 24.7 nM and induces significant differences in EFS distribution. ^[3]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
LU-139	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4HlUWlEPTB;MD6wNlM{OSEQvF2=	NXfiRo5TW0GQR1XS
NCI-H720	NGnURVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NV[xOWdLUUN3ME2wMlAzQTN6IN88US=>	MWDTRW5ITVJ?
KARPAS-45	M2Tlcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkXsTWM2OD1yLkCzN\|cyKM7:TR?=	MX7TRW5ITVJ?
EW-3	NGnGOm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mk\kTWM2OD1yLkC0NFU3KM7:TR?=	M{X2ZnNCVkeHUh?=
SBC-1	NWm4NmpwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1jDO2lEPTB;MD6wOFU5OSEQvF2=	Ml64V2FPT0WU
NCI-H209	NUDlNmZFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NH7Wc2hKSzVyPUCuNFU1PTNizszN	MVzTRW5ITVJ?
EoL-1-cell	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUPJR\|UxRTBwME[1Olkh\|ryP	MnnlV2FPT0WU
H9	NEnHfplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1fJRmlEPTB;MD6wOlY6OiEQvF2=	NXLpNFVrW0GQR1XS
AN3-CA	M{\wXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MoXtTWM2OD1yLkC3PVUyKM7:TR?=	NUDqc5E6W0GQR1XS
HH	MlXGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2L6fWlEPTB;MD6wPFAxQSEQvF2=	MlGzV2FPT0WU
KU812	MmnaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NEnPUppKSzVyPUCuNFgxPDNizszN	M4DuNnNCVkeHUh?=
DU-4475	NYHDV2hnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWXJR\|UxRTBwMEiwOFch\|ryP	NWj4Z2sxW0GQR1XS
CTV-1	NYfjcGxIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3zwemlEPTB;MD6wPFY1OSEQvF2=	MU\TRW5ITVJ?
BV-173	MnT0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYXJR\|UxRTBwMEmwOlEh\|ryP	MkKxV2FPT0WU
ES5	Mn;vS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYDNW5I5UUN3ME2wMlA6OzVizszN	MkjEV2FPT0WU
G-402	M1fhN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1PaemlEPTB;MD6wPVk5KM7:TR?=	M{T6[HNCVkeHUh?=
MV-4-11	M{ftPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHzGTVZKSzVyPUCuNVA{PDdizszN	MUnTRW5ITVJ?
NB69	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWTOUndOUUN3ME2wMlE{PSEQvF2=	NUH2VVhEW0GQR1XS
EGI-1	MlL6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{HmPWlEPTB;MD6xN\|U{OSEQvF2=	M3rWcHNCVkeHUh?=
EW-18	M4i5fGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWrJR\|UxRTBwMUSwO\|Mh\|ryP	MkjvV2FPT0WU
ME-180	NWDJUGQ3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MoXmTWM2OD1yLkG0OlgyKM7:TR?=	NFjGbYlUSU6JRWK=
D-283MED	M3fiPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MY\JR\|UxRTBwMUS3NlMh\|ryP	NYrmTWtVW0GQR1XS
NB14	MorZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHnwSJFKSzVyPUCuNVY1PDdizszN	MVXTRW5ITVJ?
Ramos-2G6-4C10	NETBfJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnTXTWM2OD1yLkG2PVg{KM7:TR?=	NHO4ZmZUSU6JRWK=
NBsusSR	NUC0VoF1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NX7lW3A{UUN3ME2wMlE4ODF7IN88US=>	MkHDV2FPT0WU
LAMA-84	NHzBXpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1HpbmlEPTB;MD6xPFA{OiEQvF2=	MVnTRW5ITVJ?
NCI-H1581	MmjOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MX3JR\|UxRTBwMUi5OlYh\|ryP	M1HYNHNCVkeHUh?=
A204	MlvUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnvtTWM2OD1yLkG4PVch\|ryP	NGjoT3pUSU6JRWK=
A549	NX;HT202T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYe1NXU2UUN3ME2wMlE6PTVizszN	M2XNU3NCVkeHUh?=
CAL-51	M{LLPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmnkTWM2OD1yLkG5OlUyKM7:TR?=	NVXEfnM3W0GQR1XS
NKM-1	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mni5TWM2OD1yLkKwNFI6KM7:TR?=	M4O4SnNCVkeHUh?=
LoVo	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUL2d2E1UUN3ME2wMlIxOjB{IN88US=>	MXjTRW5ITVJ?
HAL-01	NVXERnF4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIftTHNKSzVyPUCuNlAzQTdizszN	MmHuV2FPT0WU
HCC2218	Mnf0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYnKOWI{UUN3ME2wMlIxPjh6IN88US=>	MWPTRW5ITVJ?
BEN	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1rxZmlEPTB;MD6yNVI6OyEQvF2=	NGfKflhUSU6JRWK=
LC-2-ad	M3K2W2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXjJR\|UxRTBwMkKwPFQh\|ryP	NV:y[4JzW0GQR1XS
LXF-289	NH33e2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2LHS2lEPTB;MD6yOVA1OSEQvF2=	NYfLPZdDW0GQR1XS
HGC-27	NWjKXnM5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlTyTWM2OD1yLkK2OFE1KM7:TR?=	NXfq[ZVnW0GQR1XS
LK-2	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnK5TWM2OD1yLkK2PFI1KM7:TR?=	MY\TRW5ITVJ?
CTB-1	MlfmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWPJR\|UxRTBwMkeyNVUh\|ryP	MmLVV2FPT0WU
697	NGjud3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVzJR\|UxRTBwMkezOlch\|ryP	NF\kSIpUSU6JRWK=
ES7	NFLTdXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NH\GUZRKSzVyPUCuNlc{QDNizszN	MkTFV2FPT0WU
MG-63	NVPNXmdnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mn3KTWM2OD1yLkK3OFA4KM7:TR?=	NH;xWVBUSU6JRWK=
T47D	MmHLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{ToUmlEPTB;MD6yO\|Q4PSEQvF2=	NGj3SZpUSU6JRWK=
RPMI-8226	NUXhfFR4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1rGZ2lEPTB;MD6yPFU5QSEQvF2=	NGL5[VZUSU6JRWK=
NCI-H292	NIW4UGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NV;hVJd6UUN3ME2wMlI6OTZ2IN88US=>	NUnRU5VqW0GQR1XS
HT	M37PN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2rGfGlEPTB;MD6yPVM5KM7:TR?=	MWHTRW5ITVJ?
A3-KAW	Ml;DS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnLRTWM2OD1yLkK5O\|Qh\|ryP	M3;SdnNCVkeHUh?=
LB2241-RCC	NXPTNGx7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2T4[GlEPTB;MD6zNFE6QCEQvF2=	MkjQV2FPT0WU
BB65-RCC	NEK2[Y5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlnsTWM2OD1yLkOwPFA2KM7:TR?=	MnPlV2FPT0WU
G-401	NIT0UXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1OzfGlEPTB;MD6zNFk5PiEQvF2=	NV;zfnZnW0GQR1XS
TYK-nu	MkT1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MX7JR\|UxRTBwM{G4OlQh\|ryP	NG\oWmdUSU6JRWK=
NCI-SNU-1	NWXrNYs3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3PJT2lEPTB;MD6zNlM{OSEQvF2=	NGP4cnBUSU6JRWK=
CHL-1	MoH5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkT1TWM2OD1yLkOyO\|A{KM7:TR?=	M4HDUnNCVkeHUh?=
P30-OHK	NVjjOG95T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NW\YSm54UUN3ME2wMlMzPzB3IN88US=>	NEPaUIlUSU6JRWK=
PA-1	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmDPTWM2OD1yLkOzOlE6KM7:TR?=	MYTTRW5ITVJ?
LB1047-RCC	NWPyWIZzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4rMb2lEPTB;MD6zOFA1PyEQvF2=	MUHTRW5ITVJ?
EM-2	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYPqWVh3UUN3ME2wMlM1OTh6IN88US=>	NGDZSIFUSU6JRWK=
VA-ES-BJ	NInROmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkPGTWM2OD1yLkO0NlY5KM7:TR?=	MV\TRW5ITVJ?
NCI-H520	MmixS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mm\LTWM2OD1yLkO0PFM1KM7:TR?=	MXvTRW5ITVJ?
ECC10	NWfZUWwyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3TCOWlEPTB;MD6zOVA{PSEQvF2=	MUDTRW5ITVJ?
LNCaP-Clone-FGC	NULlR4dGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHjRXY5KSzVyPUCuN\|U{OTRizszN	Mn60V2FPT0WU
ES8	NUDLZpFqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Ml;VTWM2OD1yLkO2OVU{KM7:TR?=	NIHye4RUSU6JRWK=
HuO-3N1	NX7WXJZCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmTnTWM2OD1yLkO4N\|c6KM7:TR?=	NETZPIZUSU6JRWK=
L-363	NUDqW\|d2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Ml\nTWM2OD1yLkO5NFI3KM7:TR?=	M4rLZXNCVkeHUh?=
SK-LU-1	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MoPQTWM2OD1yLkO5NlA5KM7:TR?=	MXrTRW5ITVJ?
MCF7	NVPVXFJoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M17WVmlEPTB;MD60NFU{KM7:TR?=	NF3KU21USU6JRWK=
HuO9	NIjUSItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnzFTWM2OD1yLkSwOlY4KM7:TR?=	MYfTRW5ITVJ?
BHT-101	NIHkdYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHzwfpFKSzVyPUCuOFA4QDdizszN	M2jjfXNCVkeHUh?=
MZ2-MEL	NF3Ne\|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVz6WXhkUUN3ME2wMlQxQDh{IN88US=>	MVvTRW5ITVJ?
NOS-1	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NH[4N2dKSzVyPUCuOFExPzRizszN	MoHKV2FPT0WU
NEC8	NIDRTolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NX;xcJoyUUN3ME2wMlQyPjl3IN88US=>	MofsV2FPT0WU
COR-L88	M4XJfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2XqTmlEPTB;MD60NlI3PyEQvF2=	NVTKWlNzW0GQR1XS
MFM-223	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVvMcXBuUUN3ME2wMlQzPjF5IN88US=>	MljmV2FPT0WU
HSC-3	NEDoTmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYfJR\|UxRTBwNEK5NFgh\|ryP	MVPTRW5ITVJ?
OVCAR-5	NHL4clRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFe0VXlKSzVyPUCuOFI6OzNizszN	MVjTRW5ITVJ?
MFE-280	MkS5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MoPpTWM2OD1yLkSzNFMzKM7:TR?=	M3vpeHNCVkeHUh?=
KP-N-YS	NIfQbWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnXQTWM2OD1yLkSzNFch\|ryP	M4LzN3NCVkeHUh?=
EPLC-272H	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUG3c2RtUUN3ME2wMlQ{ODd5IN88US=>	MnzUV2FPT0WU
KE-37	NEfuVolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1fOWGlEPTB;MD60N\|I1PyEQvF2=	NEfIUpZUSU6JRWK=
HuH-7	M1zXeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWW4O5hUUUN3ME2wMlQ{Ozd{IN88US=>	NGHxXo1USU6JRWK=
CHP-212	NX;6NpA{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIHzWVdKSzVyPUCuOFM3QTdizszN	MmfBV2FPT0WU
SK-MES-1	NX;tNXNXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVvBTpBrUUN3ME2wMlQ{QDR6IN88US=>	NXvSSYp1W0GQR1XS
SJSA-1	MoHxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYDRcWJ[UUN3ME2wMlQ1PTV2IN88US=>	NYnPTFBTW0GQR1XS
QIMR-WIL	MorUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWrJR\|UxRTBwNEWxOUDPxE1?	MYPTRW5ITVJ?
ES4	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MX\JR\|UxRTBwNEWzN\|Yh\|ryP	M4fjVHNCVkeHUh?=
TI-73	NWqyUmtIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGPTcmVKSzVyPUCuOFU3QDZizszN	M2PrenNCVkeHUh?=
COLO-684	NWrHXndkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1PPSGlEPTB;MD60OVczPiEQvF2=	Mn3zV2FPT0WU
GCIY	M2\Se2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVvzOXljUUN3ME2wMlQ2PzV2IN88US=>	MYLTRW5ITVJ?
JVM-3	MonDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVTJR\|UxRTBwNE[yPVIh\|ryP	NGfLfXRUSU6JRWK=
MPP-89	Ml7FS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmPaTWM2OD1yLkS2PVQ4KM7:TR?=	M1r5[XNCVkeHUh?=
M14	MmnhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{PpTWlEPTB;MD60O\|E4KM7:TR?=	NX;uWI9yW0GQR1XS
SW962	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUPJR\|UxRTBwNEexPUDPxE1?	NEH3N45USU6JRWK=
VM-CUB-1	MnjHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3\mUWlEPTB;MD60O\|I5PiEQvF2=	M{H4VXNCVkeHUh?=
A101D	MlS3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MoX0TWM2OD1yLkS4PVY5KM7:TR?=	Mnr3V2FPT0WU
DB	NEm4cotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4\OWGlEPTB;MD61NFAzOSEQvF2=	NXfSWIN5W0GQR1XS
KNS-62	MnLHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXfJR\|UxRTBwNUC1Olgh\|ryP	MYXTRW5ITVJ?
NCI-H460	MlXnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NEnjd4VKSzVyPUCuOVA2QTdizszN	MV\TRW5ITVJ?
MDA-MB-361	NF\MboZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlXTTWM2OD1yLkWwPFch\|ryP	NEnxT29USU6JRWK=
DOK	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYDPbI1bUUN3ME2wMlUyOzN\|IN88US=>	Ml\oV2FPT0WU
CAL-39	NU\zNpFQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYrJR\|UxRTBwNUKyOlgh\|ryP	M1zIWHNCVkeHUh?=
HT-1080	M3X3eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYHJR\|UxRTBwNUK1OFMh\|ryP	NH;aWZVUSU6JRWK=
GR-ST	NUHPRll7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1jMdmlEPTB;MD61N\|AyPSEQvF2=	M3LRfnNCVkeHUh?=
J-RT3-T3-5	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWDJR\|UxRTBwNUOxPVUh\|ryP	MnTaV2FPT0WU
NCI-H1793	NVjZPIFDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NX6yUGVMUUN3ME2wMlU{PDR5IN88US=>	Ml[zV2FPT0WU
NCI-H1355	M2X2Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NILwfVZKSzVyPUCuOVM5PzhizszN	NWHnZ3ZZW0GQR1XS
YH-13	M{n0OGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVXJR\|UxRTBwNUS5N\|gh\|ryP	MnPxV2FPT0WU
LOXIMVI	Mm\YS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3m2WGlEPTB;MD61OVEzOyEQvF2=	NYnPfZF[W0GQR1XS
ES1	Mlu3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4DKSWlEPTB;MD61OVUyQCEQvF2=	NWTvVIs4W0GQR1XS
GAMG	MorDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{\Ke2lEPTB;MD61OVY2QCEQvF2=	M4rLVXNCVkeHUh?=
SK-MEL-28	M3Xlbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUf5[Zg3UUN3ME2wMlU2QTFizszN	MmLhV2FPT0WU
KG-1	NUL6SFlGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXvsPVEzUUN3ME2wMlU3QDh2IN88US=>	NXfiPWszW0GQR1XS
HOS	MlzTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVHJR\|UxRTBwNUexPVIh\|ryP	MXnTRW5ITVJ?
PANC-08-13	M3LRdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NG\sb4ZKSzVyPUCuOVc{QDlizszN	MWLTRW5ITVJ?
SW780	NFXKTItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmLiTWM2OD1yLkW3OVk2KM7:TR?=	M1LHVXNCVkeHUh?=
MDA-MB-175-VII	NHTw[25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFXRdVlKSzVyPUCuOVc4PDFizszN	NXnlcY9FW0GQR1XS
MSTO-211H	M3;CVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2jNXWlEPTB;MD61O\|c2OSEQvF2=	MU\TRW5ITVJ?
ML-2	M1P1Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2jYSWlEPTB;MD61PFQ4QCEQvF2=	M1LD[HNCVkeHUh?=
SCC-4	Mmf1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlfiTWM2OD1yLkW4OVQyKM7:TR?=	NIKxe2JUSU6JRWK=
NCI-H1048	M3nPVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWTtSJNkUUN3ME2wMlU5PjR3IN88US=>	NWS2N4pWW0GQR1XS
NCI-H28	M2Xremdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYHJR\|UxRTBwNUi2O\|Uh\|ryP	NEXHfZZUSU6JRWK=
BCPAP	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWnJR\|UxRTBwNUi3PVEh\|ryP	NWDCTVBKW0GQR1XS
PC-14	Moi5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NX\NeWtIUUN3ME2wMlU5QTdizszN	M33tW3NCVkeHUh?=
OAW-42	M1TQTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUO5O\|c4UUN3ME2wMlU6OTZ{IN88US=>	NX;neXFOW0GQR1XS
IA-LM	NWPpR5ltT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3joUGlEPTB;MD61PVYxQSEQvF2=	NFz3WYRUSU6JRWK=
Hs-578-T	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUfJR\|UxRTBwNUm4OVEh\|ryP	NUjSblFMW0GQR1XS
H4	NIPQXG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVjJR\|UxRTBwNkCwPVQh\|ryP	NIXFdHFUSU6JRWK=
HL-60	NE\rSG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHTkRoNKSzVyPUCuOlA{PTFizszN	MX;TRW5ITVJ?
NCI-H1437	MmflS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4T5d2lEPTB;MD62NFYyQSEQvF2=	NYHlXJM5W0GQR1XS
KGN	M4ftemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmmzTWM2OD1yLk[xNFQ6KM7:TR?=	MlvUV2FPT0WU
NCI-H2452	NELaXWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVPnUWE3UUN3ME2wMlYyQTF5IN88US=>	NUDEdIJEW0GQR1XS
BFTC-905	NXPpTos{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MljNTWM2OD1yLk[yNVI3KM7:TR?=	M4HDenNCVkeHUh?=
CAMA-1	NF;X[HhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWGxO3pPUUN3ME2wMlYzOTV{IN88US=>	MkPaV2FPT0WU
SK-NEP-1	MnPzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGTD[Y5KSzVyPUCuOlI2ODJizszN	MVHTRW5ITVJ?
NCI-H522	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MkOyTWM2OD1yLk[yPVkzKM7:TR?=	M3mwe3NCVkeHUh?=
SW1710	M{H3Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkW4TWM2OD1yLk[zNVY4KM7:TR?=	NX\kcXpGW0GQR1XS
RVH-421	MlPGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NX;vb2NVUUN3ME2wMlY{PjN7IN88US=>	M3P6cnNCVkeHUh?=
SK-MEL-2	NUnuW3VjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MoX0TWM2OD1yLk[0NVU{KM7:TR?=	NX7SWnF[W0GQR1XS
KYSE-150	NWC2UYQ{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{exUWlEPTB;MD62OlE5PiEQvF2=	NXfhcJBkW0GQR1XS
MOLT-13	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmDsTWM2OD1yLk[2OVM4KM7:TR?=	MWrTRW5ITVJ?
SK-OV-3	MknyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUHJR\|UxRTBwNkexPFch\|ryP	M2\DZXNCVkeHUh?=
IGROV-1	NUfVXW1ST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHT6eYVKSzVyPUCuOlc1PSEQvF2=	MmXQV2FPT0WU
MOLT-4	M3LEO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGWwWlhKSzVyPUCuOlc3QDlizszN	NFLNU21USU6JRWK=
MEL-HO	NUHreoxpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NEP0UnhKSzVyPUCuOlc4PTJizszN	NGTsdppUSU6JRWK=
MDA-MB-157	Mo\SS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NX;JeZBbUUN3ME2wMlY4QDFizszN	MUPTRW5ITVJ?
MN-60	NETubnFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnH0TWM2OD1yLk[3PFQ3KM7:TR?=	NWPhNWVTW0GQR1XS
EFO-27	NWLqSI5VT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3vKfmlEPTB;MD62O\|k4QSEQvF2=	M1nUSXNCVkeHUh?=
HO-1-N-1	NF7md3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIPmTZNKSzVyPUCuOlgxPjRizszN	MVfTRW5ITVJ?
TE-5	NHHufZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MY\JR\|UxRTBwNki0NFUh\|ryP	MoCyV2FPT0WU
EW-22	NYP4PYxiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MojwTWM2OD1yLk[4OFQ1KM7:TR?=	NELCbppUSU6JRWK=
SW982	M2LVWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWjJR\|UxRTBwNki1NFEh\|ryP	M1PDZ3NCVkeHUh?=
SF295	NFPLW3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVrIWGU1UUN3ME2wMlY5PTB5IN88US=>	MkjFV2FPT0WU
WM-115	NYKzcXAxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnvmTWM2OD1yLk[4PVI1KM7:TR?=	M4\KdHNCVkeHUh?=
COLO-800	MkHsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NEHnOnRKSzVyPUCuOlk5OTNizszN	MofaV2FPT0WU
NTERA-S-cl-D1	MnHsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUXJR\|UxRTBwN{CwOlMh\|ryP	Mmm0V2FPT0WU
NCI-H1648	NXPmUIFvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MV3JR\|UxRTBwN{CxO\|Mh\|ryP	MnTxV2FPT0WU
NB5	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3K2bGlEPTB;MD63NFMyQSEQvF2=	M33BbXNCVkeHUh?=
ATN-1	NYW2ZnJHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUDjW45JUUN3ME2wMlcxPTlizszN	MUHTRW5ITVJ?
NUGC-3	M4fi[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVTPR2RZUUN3ME2wMlcxPjlzIN88US=>	NUnPSZR6W0GQR1XS
22RV1	M1XhWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1nXcmlEPTB;MD63NFcyPyEQvF2=	M1qy[XNCVkeHUh?=
8305C	M4[wfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXLJR\|UxRTBwN{C3OVUh\|ryP	NWK5do5kW0GQR1XS
EFM-19	NVTUTZo3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYfER4p5UUN3ME2wMlcxQDR5IN88US=>	M4XKRnNCVkeHUh?=
PC-3	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MU\JR\|UxRTBwN{KyN{DPxE1?	Mn31V2FPT0WU
C32	NIjKOJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkfWTWM2OD1yLkeyOFg1KM7:TR?=	MkjUV2FPT0WU
MC-IXC	NWH0SlNXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3\rXWlEPTB;MD63NlcyQCEQvF2=	NYK2SXlZW0GQR1XS
OMC-1	NGPXb5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NEewSoNKSzVyPUCuO\|I4OzhizszN	MVjTRW5ITVJ?
HTC-C3	NWr1NXR4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2XURWlEPTB;MD63N\|E4OiEQvF2=	MX3TRW5ITVJ?
RPMI-7951	Mn:yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHTpS\|BKSzVyPUCuO\|M2OzNizszN	NFO5SFNUSU6JRWK=
AsPC-1	M1zVV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2K0UmlEPTB;MD63N\|c6PSEQvF2=	MX7TRW5ITVJ?
CAKI-1	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWPZepBSUUN3ME2wMlc1PjJ7IN88US=>	M4fHeHNCVkeHUh?=
MHH-PREB-1	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4jSTGlEPTB;MD63OFc{PiEQvF2=	MV3TRW5ITVJ?
HLE	NHXGSGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVfJR\|UxRTBwN{S4OFQh\|ryP	NHLHbVVUSU6JRWK=
A375	NVj5eZJvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVjsXXA6UUN3ME2wMlc2OTl\|IN88US=>	MYTTRW5ITVJ?
RS4-11	NUCxWlA6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXL5[HZuUUN3ME2wMlc2QTR\|IN88US=>	NXfWZlNlW0GQR1XS
U-2-OS	MmLxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWLJR\|UxRTBwN{W5O{DPxE1?	Mm\NV2FPT0WU
NCI-H747	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYj3O\|dIUUN3ME2wMlc2QTlzIN88US=>	M{L5dXNCVkeHUh?=
NCI-H1623	M3O4S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NInCUHVKSzVyPUCuO\|YzPjFizszN	MVnTRW5ITVJ?
DMS-273	Mo\1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2q4cmlEPTB;MD63OlkzOiEQvF2=	NYXEbGxpW0GQR1XS
PSN1	NETPW2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NE\KOmxKSzVyPUCuO\|cxPTdizszN	M{fOd3NCVkeHUh?=
LU-99A	NY\MPGxqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkXETWM2OD1yLke3OlQ6KM7:TR?=	MWTTRW5ITVJ?
CAL-12T	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVrmb\|V6UUN3ME2wMlc5ODJ7IN88US=>	MWDTRW5ITVJ?
KYSE-140	NV7BVlVNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmqwTWM2OD1yLke4NVY5KM7:TR?=	M4jiN3NCVkeHUh?=
VMRC-RCZ	M4fMOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVP1e2ZiUUN3ME2wMlc5PDh{IN88US=>	M3LqTXNCVkeHUh?=
Ca9-22	M2XUOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUnDdGdjUUN3ME2wMlc5PzN4IN88US=>	MYHTRW5ITVJ?
NCI-H1563	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXi2RZNrUUN3ME2wMlc5QTJ4IN88US=>	MUTTRW5ITVJ?
NCI-H650	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MV3JR\|UxRTBwN{mxOFQh\|ryP	MVnTRW5ITVJ?
DOHH-2	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NV7Q[5RFUUN3ME2wMlc6OzNizszN	MYDTRW5ITVJ?
OE33	NY\0Vo5MT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVvTVVVNUUN3ME2wMlc6QTF2IN88US=>	M4HUNHNCVkeHUh?=
CAL-62	M1m1WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NEn0eXVKSzVyPUCuO\|k6OjRizszN	M371[HNCVkeHUh?=
NCI-H1770	M13z[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYTJR\|UxRTBwOECyNUDPxE1?	M3vmZ3NCVkeHUh?=
SN12C	NFqyZ5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUHJWVZ3UUN3ME2wMlgxPjZ6IN88US=>	M1nyUHNCVkeHUh?=
HPAF-II	NF7oWG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVnJR\|UxRTBwOEC3PVQh\|ryP	M3HMNXNCVkeHUh?=
SNU-423	NVjWOWNUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVPJR\|UxRTBwOEG0NlIh\|ryP	NGr6XWNUSU6JRWK=
A704	NGjDOHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmiwTWM2OD1yLkixO\|k5KM7:TR?=	M{n6ZXNCVkeHUh?=
OVCAR-4	NI\T[phIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MonvTWM2OD1yLkixPVEyKM7:TR?=	M1:wc3NCVkeHUh?=
NCI-H2347	M{TSZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1zLTWlEPTB;MD64NlQxOSEQvF2=	M3TBdHNCVkeHUh?=
OCUB-M	NF\MO\|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MULJR\|UxRTBwOEK2O\|Uh\|ryP	M1;4[3NCVkeHUh?=
KYSE-450	NXTIZ4dNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXzwRXh4UUN3ME2wMlgzPzJ3IN88US=>	M372ZXNCVkeHUh?=
PFSK-1	NVPiTIpqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3P0TGlEPTB;MD64N\|A{QSEQvF2=	NHr3SGpUSU6JRWK=
A431	MmH4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1LWUWlEPTB;MD64N\|EyPiEQvF2=	NX7uSmhsW0GQR1XS
MHH-ES-1	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXLJR\|UxRTBwOEO0OVch\|ryP	MnvCV2FPT0WU
HD-MY-Z	M3PtPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3\CcWlEPTB;MD64OFA6OiEQvF2=	NIjUVVBUSU6JRWK=
RT-112	M3q0dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M13TUWlEPTB;MD64OFk{PyEQvF2=	NYrLNlhMW0GQR1XS
KU-19-19	NXzrT2pMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Ml;NTWM2OD1yLki1NVIyKM7:TR?=	M3HtVHNCVkeHUh?=
HCC1569	NI\hW2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmPUTWM2OD1yLki1NlA4KM7:TR?=	MlHMV2FPT0WU
RPMI-8866	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVjJR\|UxRTBwOEW4NlIh\|ryP	NWKyfIFTW0GQR1XS
CAL-120	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4\BUWlEPTB;MD64OlA1OSEQvF2=	Moj4V2FPT0WU
CAL-33	M3n0U2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mn[2TWM2OD1yLki2OFk2KM7:TR?=	M3PyUHNCVkeHUh?=
RKO	NWH2dJV1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MW\JR\|UxRTBwOE[4NVch\|ryP	MV7TRW5ITVJ?
HCC1419	NYHkc5dnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVTOSlkxUUN3ME2wMlg3QTJ6IN88US=>	M1rUd3NCVkeHUh?=
CP50-MEL-B	Ml;ES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmjQTWM2OD1yLki4N\|g1KM7:TR?=	NU[0VIZUW0GQR1XS
BPH-1	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4fte2lEPTB;MD64PFM6PSEQvF2=	MljGV2FPT0WU
SF126	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWTJR\|UxRTBwOEi3NVQh\|ryP	NYHwSo5nW0GQR1XS
BHY	Mlr2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXnBeI0zUUN3ME2wMlg5PzN2IN88US=>	MkPnV2FPT0WU
BxPC-3	M4K5Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUX4dVVnUUN3ME2wMlg5QDN\|IN88US=>	MljQV2FPT0WU
ETK-1	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NF7lU5lKSzVyPUCuPFk{PzJizszN	MYnTRW5ITVJ?
NCI-H1573	NHv6NlVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFPSN2xKSzVyPUCuPVAzOjlizszN	MW\TRW5ITVJ?
C-33-A	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4HWcWlEPTB;MD65NFQ1OiEQvF2=	MlflV2FPT0WU
UACC-893	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{jCU2lEPTB;MD65Nlg2PSEQvF2=	MWfTRW5ITVJ?
RXF393	NVPnWHRrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MorsTWM2OD1yLkmyPFk4KM7:TR?=	NGDkU3FUSU6JRWK=
MIA-PaCa-2	NEnpV3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGnpNVZKSzVyPUCuPVI6OjJizszN	MoTCV2FPT0WU
HCC1806	NXvkUmY5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mm\hTWM2OD1yLkmzNlU3KM7:TR?=	M4fFSXNCVkeHUh?=
DMS-114	NYnLcWhxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NULqTYpEUUN3ME2wMlk{Pjd5IN88US=>	MV\TRW5ITVJ?
MOLT-16	NHrnSWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1jITmlEPTB;MD65N\|g1PSEQvF2=	MnjyV2FPT0WU
ACN	NXPrOmtZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYDJR\|UxRTBwOUSyO\|ch\|ryP	NVLvUmQzW0GQR1XS
SNU-449	NED4S49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkOxTWM2OD1yLkm1PVI1KM7:TR?=	NELZR2hUSU6JRWK=
A427	NITidmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUX6N5J{UUN3ME2wMlk3OTl6IN88US=>	MlLmV2FPT0WU
DEL	NWDvZ294T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3LJc2lEPTB;MD65Olc4OyEQvF2=	NWjTUXBKW0GQR1XS
NCI-H1792	M2nL[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUjJR\|UxRTBwOUexNFEh\|ryP	MmPpV2FPT0WU
A2058	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmPKTWM2OD1yLkm3N\|Yh\|ryP	NWq2UFBxW0GQR1XS
SW13	M3TpR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NV\lXWE2UUN3ME2wMlk5Ozl{IN88US=>	M1XYb3NCVkeHUh?=
T98G	M{T1dWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVjWeIF3UUN3ME2xMlAyOzZ2IN88US=>	M{\lSHNCVkeHUh?=
LU-134-A	M4XwV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFHrRWRKSzVyPUGuNFI3PzVizszN	NX7NfHJ1W0GQR1XS
GI-ME-N	NV6zbmtET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnuyTWM2OD1zLkCyPFI4KM7:TR?=	MWDTRW5ITVJ?
D-423MG	NVf4ZmtUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NY\0b3dWUUN3ME2xMlAzQTZ\|IN88US=>	NF7wZ3JUSU6JRWK=
PANC-03-27	M2T5Xmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1fKWGlEPTB;MT6wN\|E1OSEQvF2=	Moe5V2FPT0WU
P12-ICHIKAWA	NEXRfYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUjJR\|UxRTFwMEO0NFYh\|ryP	M3THcnNCVkeHUh?=
SCH	MnnZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2ruNGlEPTB;MT6wN\|Q2KM7:TR?=	M3:ye3NCVkeHUh?=
D-566MG	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{W1SGlEPTB;MT6wOlczPiEQvF2=	MXXTRW5ITVJ?
OS-RC-2	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYDSdFduUUN3ME2xMlA4QTRizszN	MYDTRW5ITVJ?
KOSC-2	NX;KPWNsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWDVboYzUUN3ME2xMlA5ODJzIN88US=>	NWiyR\|BiW0GQR1XS
SH-4	NGPiRXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVewVpRqUUN3ME2xMlA5PDNzIN88US=>	MnXYV2FPT0WU
786-0	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Ml;PTWM2OD1zLkC4PVM1KM7:TR?=	NUPIOHQ2W0GQR1XS
Mewo	MlzKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3ixXGlEPTB;MT6wPVI1QCEQvF2=	MlzwV2FPT0WU
AGS	NXLWUJJMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHy0UolKSzVyPUGuNFk1PTlizszN	M4PWTXNCVkeHUh?=
Daoy	NVHTUWY4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWTo[GRMUUN3ME2xMlA6PjJ6IN88US=>	Mn;jV2FPT0WU
SW48	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGDyT41KSzVyPUGuNVA6OTFizszN	M2LyfHNCVkeHUh?=
KYSE-180	MkLzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{\3cGlEPTB;MT6xNVAzOSEQvF2=	MnHuV2FPT0WU
NH-12	M3u2PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnfhTWM2OD1zLkGxNlM4KM7:TR?=	MY\TRW5ITVJ?
BE-13	M1\k[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGeyepdKSzVyPUGuNVE4PTlizszN	M3nxSHNCVkeHUh?=
ES3	NXrmSZpnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MW\JR\|UxRTFwMUOxO\|Eh\|ryP	NWrmZXpPW0GQR1XS
NCI-H1092	NV2xU5o4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYHJR\|UxRTFwMUO0JO69VQ>?	MlnYV2FPT0WU
NCI-H1755	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1\vRWlEPTB;MT6xN\|k1OSEQvF2=	MnnyV2FPT0WU
EKVX	NYLROWI6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYTxNWhkUUN3ME2xMlE1ODBzIN88US=>	M1jROnNCVkeHUh?=
NB13	MlT4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHvHSmFKSzVyPUGuNVQ1PSEQvF2=	NIrZZpBUSU6JRWK=
NCI-H2405	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVnJR\|UxRTFwMUS1O\|Qh\|ryP	NFzLO2dUSU6JRWK=
LS-411N	NIL4OGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUXUPIR5UUN3ME2xMlE2ODF5IN88US=>	MUPTRW5ITVJ?
MDA-MB-453	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVLtWVVuUUN3ME2xMlE2PjJ2IN88US=>	M2joZnNCVkeHUh?=
SCC-15	NWnoOXNCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFy0NYRKSzVyPUGuNVY6PTZizszN	MVPTRW5ITVJ?
C2BBe1	NIDUUYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFr3emRKSzVyPUGuNVcxPTZizszN	MX3TRW5ITVJ?
HT-144	MnvtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkjGTWM2OD1zLkG3NFch\|ryP	NGrTcmZUSU6JRWK=
HEC-1	M3WwZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1zpTWlEPTB;MT6xO\|YzPyEQvF2=	NWrFZ2F3W0GQR1XS
HCE-T	Ml;wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3jSfWlEPTB;MT6xO\|k5OyEQvF2=	NHvDOWtUSU6JRWK=
IST-MEL1	MkLXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYTJR\|UxRTFwMUmwPFIh\|ryP	MlPzV2FPT0WU
Detroit562	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHvMVmhKSzVyPUGuNVk1OzlizszN	M{\5SnNCVkeHUh?=
A4-Fuk	MojES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIezSGhKSzVyPUGuNlA1PDFizszN	M1qwVnNCVkeHUh?=
HDLM-2	NGLmSXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MorqTWM2OD1zLkKxN\|I3KM7:TR?=	MlnWV2FPT0WU
MKN7	MlzMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4HW[GlEPTB;MT6yNVcxOiEQvF2=	NHfJOnVUSU6JRWK=
MDA-MB-415	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mkj2TWM2OD1zLkKxO\|AzKM7:TR?=	NES0TWlUSU6JRWK=
BT-20	NFrJUpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{LTeGlEPTB;MT6yNlQ1PCEQvF2=	MnjXV2FPT0WU
NCI-H2030	NHLhbmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWS3TmhDUUN3ME2xMlI1OTB4IN88US=>	Mn;6V2FPT0WU
LS-123	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MoDRTWM2OD1zLkK0O\|U{KM7:TR?=	MlHQV2FPT0WU
SK-MEL-3	NGjzUGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHTHbGZKSzVyPUGuNlQ4PzZizszN	MVvTRW5ITVJ?
KS-1	M{XvWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnfHTWM2OD1zLkK1NVcyKM7:TR?=	MXvTRW5ITVJ?
LU-65	M1PCNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NV;0e3FKUUN3ME2xMlI2PjB4IN88US=>	MV3TRW5ITVJ?
NCI-H596	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXvJR\|UxRTFwMkW5Nlkh\|ryP	MlHCV2FPT0WU
KYSE-410	Mn;DS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1fneGlEPTB;MT6yO\|AyPCEQvF2=	MVHTRW5ITVJ?
NCI-H2228	NHnyXXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIXuelhKSzVyPUGuNlcyPjdizszN	Mnr3V2FPT0WU
LN-405	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXvJR\|UxRTFwMkiwNlEh\|ryP	NYLmOIJCW0GQR1XS
8505C	NHvFR4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVTJR\|UxRTFwMki4NlMh\|ryP	NWTub4poW0GQR1XS
BFTC-909	NVLVU\|RZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmmzTWM2OD1zLkK5OFM1KM7:TR?=	NWL6eGdEW0GQR1XS
OC-314	M13RbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWH3[ZBJUUN3ME2xMlI6QTJ7IN88US=>	Mnv1V2FPT0WU
NMC-G1	MkDZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGXDZ\|JKSzVyPUGuN\|EyOzVizszN	NIHwXJZUSU6JRWK=
SKG-IIIa	M4T5cWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYWwOJF1UUN3ME2xMlMyPDJ6IN88US=>	MWjTRW5ITVJ?
GAK	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmHKTWM2OD1zLkOxPFU5KM7:TR?=	MkPNV2FPT0WU
D-263MG	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NIr4OWZKSzVyPUGuN\|I3PDFizszN	NVLiUXVbW0GQR1XS
NCI-H446	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MY\JR\|UxRTFwM{K5NFIh\|ryP	MlHOV2FPT0WU
TGBC1TKB	M3zHPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NW\JSm1WUUN3ME2xMlMzQTl6IN88US=>	MXzTRW5ITVJ?
GCT	MojtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmXzTWM2OD1zLkO0N\|Q2KM7:TR?=	MoPwV2FPT0WU
COR-L23	NGnGWZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1jVPWlEPTB;MT6zOFg1PSEQvF2=	M3\kfXNCVkeHUh?=
TK10	NGricW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3HTc2lEPTB;MT6zOVc6PyEQvF2=	M3PD[nNCVkeHUh?=
ES6	NX3z[VZDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUDJR\|UxRTFwM{[zO\|Yh\|ryP	MnvOV2FPT0WU
SW1088	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHPYXpFKSzVyPUGuN\|Y3OTJizszN	M4\6dnNCVkeHUh?=
AM-38	NGfBOWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVPxeIdKUUN3ME2xMlM4OTl7IN88US=>	M2LsOnNCVkeHUh?=
CHP-134	NIXL[\|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYfJR\|UxRTFwM{e4OFQh\|ryP	MXXTRW5ITVJ?
SW872	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MoHxTWM2OD1zLkO4OVU2KM7:TR?=	M2K0eHNCVkeHUh?=
LB831-BLC	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXnO[2xoUUN3ME2xMlM6ODZ5IN88US=>	Ml;EV2FPT0WU
TE-12	NHnYW2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYTJR\|UxRTFwNEC2NFEh\|ryP	NHrhUlZUSU6JRWK=
LCLC-97TM1	NFrzUIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWq0XIJPUUN3ME2xMlQyODR4IN88US=>	MYLTRW5ITVJ?
HCT-116	M1vES2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MoTYTWM2OD1zLkSyPFU1KM7:TR?=	MV3TRW5ITVJ?
ALL-PO	NVLlOnVTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{\jcGlEPTB;MT60N\|c4PCEQvF2=	MnK3V2FPT0WU
EW-16	NWXyc3RQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlHaTWM2OD1zLkSzPFQzKM7:TR?=	Mn7wV2FPT0WU
NCI-H661	MlrBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYXJR\|UxRTFwNES3O\|Uh\|ryP	MWnTRW5ITVJ?
TE-8	M3u1c2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVrJR\|UxRTFwNEW1OkDPxE1?	NIfnfWdUSU6JRWK=
TCCSUP	Ml7QS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWe5VZNvUUN3ME2xMlQ3QTZizszN	M{nKdHNCVkeHUh?=
SW1990	NUjXToNGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFTCUplKSzVyPUGuOFc2OzNizszN	NEjaOmFUSU6JRWK=
UM-UC-3	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NULzNYRzUUN3ME2xMlQ4Pjd3IN88US=>	MVzTRW5ITVJ?
HuP-T4	Ml7tS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2mwRWlEPTB;MT60PFYxPyEQvF2=	MnPKV2FPT0WU
NCI-H1299	NVu3WWd{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVXJR\|UxRTFwNUCwPFYh\|ryP	NUfPNlhtW0GQR1XS
RO82-W-1	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWS1e\|B7UUN3ME2xMlUzODhzIN88US=>	NH3CfGFUSU6JRWK=
Becker	MmDPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWHBXWJPUUN3ME2xMlUzOTh5IN88US=>	M{LTPXNCVkeHUh?=
SNU-387	Mk\aS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2jMWWlEPTB;MT61NlI1OSEQvF2=	NFnmUnpUSU6JRWK=
CAL-85-1	NHXz[2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkX6TWM2OD1zLkWyOVk6KM7:TR?=	NELndJZUSU6JRWK=
647-V	NYnSbI5zT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUPNPFF6UUN3ME2xMlU{QDhizszN	MnTEV2FPT0WU
SBC-5	NV\jWolRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmHtTWM2OD1zLkW0OVk{KM7:TR?=	NF7YbW5USU6JRWK=
NCI-H23	NXfNSFVVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYTJR\|UxRTFwNUW3NVQh\|ryP	MWLTRW5ITVJ?
CGTH-W-1	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGCxUmNKSzVyPUGuOVU5OTlizszN	Mk[4V2FPT0WU
SK-N-FI	MlvoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MX;JR\|UxRTFwNUW5NFgh\|ryP	MV3TRW5ITVJ?
KM-H2	NF\mVphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnXUTWM2OD1zLkW2OFc1KM7:TR?=	MlvNV2FPT0WU
KY821	NW\HN28{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4SxbGlEPTB;MT61OlYyPyEQvF2=	MUTTRW5ITVJ?
RH-1	NVPZV5llT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{HUO2lEPTB;MT61Olc3OiEQvF2=	MYTTRW5ITVJ?
KYSE-270	Mn3lS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWfxOGdOUUN3ME2xMlU4PDJ\|IN88US=>	M{DmS3NCVkeHUh?=
SF539	M2DON2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFrCZo5KSzVyPUGuOVc6PjlizszN	NG\JWI1USU6JRWK=
JEG-3	NVO1OmdmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NX3o[ZhqUUN3ME2xMlU5ODl2IN88US=>	M3LpbXNCVkeHUh?=
SCC-25	Ml\BS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmntTWM2OD1zLkW4OFMzKM7:TR?=	NGXtS5pUSU6JRWK=
SW1573	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXzXOJdIUUN3ME2xMlYxOTV6IN88US=>	M33pW3NCVkeHUh?=
EW-1	NFTv[2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkfOTWM2OD1zLk[xN\|UyKM7:TR?=	MX;TRW5ITVJ?
YKG-1	M2DsNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVPJR\|UxRTFwNkG0N\|gh\|ryP	NGjPcI1USU6JRWK=
EW-11	NFTHbXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mkf0TWM2OD1zLk[xO\|QyKM7:TR?=	Mn7yV2FPT0WU
DJM-1	NFvQbWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MX3JR\|UxRTFwNkG4NlUh\|ryP	NGi3Om9USU6JRWK=
Calu-3	NEXwTpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVPJR\|UxRTFwNkWyNVMh\|ryP	NUexR48yW0GQR1XS
HT-3	M1jleWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVnJR\|UxRTFwNkW2OkDPxE1?	M4G3ZXNCVkeHUh?=
NCI-H69	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mn:2TWM2OD1zLk[3N\|Q{KM7:TR?=	Moe0V2FPT0WU
NCI-H2126	Mn7vS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{\2NWlEPTB;MT62O\|c6PyEQvF2=	NXzZSWJFW0GQR1XS
RPMI-2650	M2K4SGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mmq4TWM2OD1zLk[4N\|E4KM7:TR?=	MkftV2FPT0WU
TE-6	NIfqSlRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWHJR\|UxRTFwN{C4O\|Qh\|ryP	M{HoenNCVkeHUh?=
MDA-MB-231	NW[yXGlDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mny2TWM2OD1zLkexPVk{KM7:TR?=	M4OwfHNCVkeHUh?=
A2780	M3;hcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmPqTWM2OD1zLkeyNlA4KM7:TR?=	M1zyXnNCVkeHUh?=
GOTO	NYraTIdkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVLkW\|hDUUN3ME2xMlc{PTZizszN	NEO3Z5BUSU6JRWK=
KYSE-70	MlK3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NISyfVRKSzVyPUGuO\|Q1PDJizszN	MYHTRW5ITVJ?
GMS-10	NUG3R4h[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHXkNJRKSzVyPUGuO\|Q3PjJizszN	NIP4Z3pUSU6JRWK=
CaR-1	MoXWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWPJR\|UxRTFwN{S4NVIh\|ryP	MVvTRW5ITVJ?
SW900	M3PRWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlL2TWM2OD1zLke0PVk{KM7:TR?=	M1S1d3NCVkeHUh?=
BB49-HNC	NWqyeJRZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWHTSZFkUUN3ME2xMlc2OTZ6IN88US=>	MXTTRW5ITVJ?
SNB75	NWOybnVUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NU\FW2tLUUN3ME2xMlc2PDl{IN88US=>	NVLLd5lKW0GQR1XS
SK-PN-DW	Mn61S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2rHS2lEPTB;MT63OVY5OiEQvF2=	NGjIOFVUSU6JRWK=
5637	NYLqPI5ZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M37sVGlEPTB;MT63O\|I3QCEQvF2=	M2HQRXNCVkeHUh?=
BT-474	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NV[2dZFlUUN3ME2xMlc5OTdzIN88US=>	MXXTRW5ITVJ?
KM12	NIPv[5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4ntUGlEPTB;MT63PVc1OSEQvF2=	MUPTRW5ITVJ?
COLO-680N	MoXYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NILsdoxKSzVyPUGuPFI{QDFizszN	M1zme3NCVkeHUh?=
Saos-2	NXjPfGVNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmfvTWM2OD1zLkiyOFQ2KM7:TR?=	MmnQV2FPT0WU
CAL-54	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVr6V4dRUUN3ME2xMlg{OzF\|IN88US=>	MWnTRW5ITVJ?
U-118-MG	NVfOSJliT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXXsVYtCUUN3ME2xMlg1PjJ{IN88US=>	MYPTRW5ITVJ?
TGBC24TKB	NEL1TWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NEf1cmxKSzVyPUGuPFU2ODFizszN	NGjIPZNUSU6JRWK=
NCI-H2052	NFL2fXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXjJR\|UxRTFwOE[0NUDPxE1?	NFjWT4pUSU6JRWK=
BB30-HNC	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnzrTWM2OD1zLki2OFYzKM7:TR?=	NVjKem9UW0GQR1XS
KNS-81-FD	NGf5[pZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4eybmlEPTB;MT64PVE3PSEQvF2=	MljjV2FPT0WU
HN	MlH1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUHJR\|UxRTFwOEm1OFUh\|ryP	M2XTfnNCVkeHUh?=
ACHN	M2fYbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlLtTWM2OD1zLkmwO\|g3KM7:TR?=	NVjvOI43W0GQR1XS
HSC-2	NXjsUpdiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWPJR\|UxRTFwOUGwPVYh\|ryP	M1nsSnNCVkeHUh?=
HCC2998	NIG2O\|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmLVTWM2OD1zLkmzN\|I2KM7:TR?=	M3P1WHNCVkeHUh?=
HEL	NX65WJVST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFn1WGJKSzVyPUGuPVQyQDRizszN	NXLNfod3W0GQR1XS
SW684	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHy1SZRKSzVyPUGuPVc{PzFizszN	M3jM[nNCVkeHUh?=
NCI-H1693	NILL[25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1rxeGlEPTB;MT65PFA5PiEQvF2=	M3LaZnNCVkeHUh?=
8-MG-BA	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWToZ21vUUN3ME2xMlk5OjFizszN	MVTTRW5ITVJ?
OVCAR-8	NVHrS3pqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYjJR\|UxRTJwMECyPVUh\|ryP	NH7qW5RUSU6JRWK=
DSH1	NXrx[nkxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHrqSGNKSzVyPUKuNFE4PzRizszN	M2[y[3NCVkeHUh?=
KYSE-520	M1jJW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYnoOYg5UUN3ME2yMlAzODR7IN88US=>	MoDzV2FPT0WU
GB-1	NWn3SHlKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{jRZWlEPTB;Mj6wNlU4PyEQvF2=	M1H6RnNCVkeHUh?=
RCC10RGB	Ml7KS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NV;Xd2V6UUN3ME2yMlA1QDdzIN88US=>	NEXueWpUSU6JRWK=
SW954	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3uxbGlEPTB;Mj6wOVA{PiEQvF2=	MmrjV2FPT0WU
IST-MES1	M{fTcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVnpNXhUUUN3ME2yMlA2PTZ6IN88US=>	NVXWZ3Q5W0GQR1XS
AU565	NEnUcnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MoTWTWM2OD1{LkC1PVA2KM7:TR?=	MXjTRW5ITVJ?
CW-2	NE\LZm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXjJR\|UxRTJwME[4O\|Uh\|ryP	NFvOXlJUSU6JRWK=
TE-1	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYK0c2pZUUN3ME2yMlA6Ozd5IN88US=>	NHP5ZWxUSU6JRWK=
KP-4	MmDqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MoLITWM2OD1{LkGwN\|EzKM7:TR?=	NGHKfGdUSU6JRWK=
SNU-C2B	NYnJNXpQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{i2cmlEPTB;Mj6xNFgzOyEQvF2=	NH:5bIhUSU6JRWK=
NCI-H1395	MonPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlTzTWM2OD1{LkGwPVg3KM7:TR?=	MUjTRW5ITVJ?
CAS-1	NG\mOppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWfJR\|UxRTJwMUG1OFYh\|ryP	MV3TRW5ITVJ?
NCI-H1155	NF31U21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mlj0TWM2OD1{LkKyOlkh\|ryP	M{TGdHNCVkeHUh?=
SK-MEL-1	NVP5So15T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUnKdoV5UUN3ME2yMlI5OThzIN88US=>	NVT1ZlhZW0GQR1XS
KINGS-1	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWXJR\|UxRTJwM{CwPFgh\|ryP	NIjRZndUSU6JRWK=
ESS-1	NUnhSVFzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVLJR\|UxRTJwM{C1NUDPxE1?	M4DqeXNCVkeHUh?=
PANC-10-05	NF7WdG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmDXTWM2OD1{LkO3NFI1KM7:TR?=	NYjhfI9pW0GQR1XS
HT-1376	NUOySmxzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{XmfmlEPTB;Mj6zPFcxQCEQvF2=	M3nPe3NCVkeHUh?=
LS-513	NXTnSYp[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYL3UIxVUUN3ME2yMlM5QDd2IN88US=>	NFjkOZlUSU6JRWK=
KNS-42	M3HWVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYHzOXZWUUN3ME2yMlM6OTB3IN88US=>	MYXTRW5ITVJ?
639-V	Ml;yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHzzTY9KSzVyPUKuOFI4PThizszN	MVfTRW5ITVJ?
SJRH30	MojuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NEL3VmdKSzVyPUKuOFUyPjFizszN	M{LEcnNCVkeHUh?=
SW1783	M2jYdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHG5OoZKSzVyPUKuOFcxPzhizszN	NYPFOmFYW0GQR1XS
NB6	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1\MbmlEPTB;Mj60PFI5KM7:TR?=	MYjTRW5ITVJ?
SK-MEL-30	M2jhd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2nGUWlEPTB;Mj60PFg{KM7:TR?=	NGHCSFJUSU6JRWK=
HCE-4	M3jQT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIjhT4NKSzVyPUKuOFk1ODJizszN	NYP4b5hWW0GQR1XS
NB10	NHXQbJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYC0fZFjUUN3ME2yMlQ6PDJ7IN88US=>	NFnpTWNUSU6JRWK=
H-EMC-SS	NXq5N\|V3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmrMTWM2OD1{LkW0OlUh\|ryP	NInSfFVUSU6JRWK=
SK-HEP-1	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXjJR\|UxRTJwNUWyN\|Yh\|ryP	NEmzSmhUSU6JRWK=
HCC1395	M3HMV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFzyeGRKSzVyPUKuOVU3PTVizszN	M4jyRXNCVkeHUh?=
HuCCT1	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{jNSWlEPTB;Mj61OlM6KM7:TR?=	NU\Y[GNrW0GQR1XS
SiHa	MmXaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1\PR2lEPTB;Mj61PFcyQSEQvF2=	M2fueXNCVkeHUh?=
EFO-21	M2nvOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGXLVW1KSzVyPUKuOVg4PjRizszN	NGfqTldUSU6JRWK=
NCI-H1666	NFPGW4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MoDjTWM2OD1{LkW5NFc3KM7:TR?=	NU\BXolkW0GQR1XS
UMC-11	M3nJR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlrCTWM2OD1{LkW5PFY5KM7:TR?=	M4DGVnNCVkeHUh?=
COLO-679	M1L0e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWnWSY5yUUN3ME2yMlYyOjN\|IN88US=>	NGS2WZVUSU6JRWK=
A388	MkfiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHjk[\|JKSzVyPUKuOlUzPTNizszN	MkiwV2FPT0WU
LB2518-MEL	NH;CZWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYDJR\|UxRTJwNkW0NFgh\|ryP	MV;TRW5ITVJ?
EW-13	M1izWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFjhb21KSzVyPUKuOlg4PjhizszN	NXrmXXlFW0GQR1XS
MLMA	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYHQ[IR5UUN3ME2yMlY5QDV4IN88US=>	MWfTRW5ITVJ?
HOP-92	NUX4VoZTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVzJR\|UxRTJwN{CxNUDPxE1?	NXPmb3RHW0GQR1XS
NOMO-1	M3[xe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXPLWodxUUN3ME2yMlcyPDR{IN88US=>	M2j0OHNCVkeHUh?=
NCI-H810	MlznS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1XTNWlEPTB;Mj63NlE6QCEQvF2=	NUHDc5RzW0GQR1XS
769-P	NYDHTYdCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXvLfllJUUN3ME2yMlczOjhizszN	MWnTRW5ITVJ?
SAS	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXiwbGV3UUN3ME2yMlc3PSEQvF2=	NUPjVXdGW0GQR1XS
M059J	NWrRe21KT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NILQbotKSzVyPUKuO\|g{OThizszN	NXPwTmVkW0GQR1XS
RD	NFrMZ4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3XyW2lEPTB;Mj63PVQ4OSEQvF2=	MXHTRW5ITVJ?
GT3TKB	Mof1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MW\JR\|UxRTJwOEO0N\|Mh\|ryP	M{i2bnNCVkeHUh?=
MZ7-mel	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYTJR\|UxRTJwOE[1NFIh\|ryP	M4LGbHNCVkeHUh?=
KYSE-510	NFfn[IxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MX7JR\|UxRTJwOEm1NFQh\|ryP	NVzyT45UW0GQR1XS
NCI-N87	NGXCOW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mn7zTWM2OD1{LkmxPFA4KM7:TR?=	M1;VW3NCVkeHUh?=
MKN1	MlfWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NF3qXohKSzVyPUOuNFAyPjNizszN	NUPuZ4JPW0GQR1XS
NCI-H2170	NInWWHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{j3dWlEPTB;Mz6wNFQ2OSEQvF2=	MofEV2FPT0WU
OVCAR-3	NXzITmtvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NEjwPJpKSzVyPUOuNFIyOTVizszN	NGjhUXVUSU6JRWK=
KLE	M1y0bGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmjpTWM2OD1\|LkC2PFEzKM7:TR?=	NEDwS\|VUSU6JRWK=
LB771-HNC	NEOwTWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmGyTWM2OD1\|LkC5N\|Q{KM7:TR?=	MmfkV2FPT0WU
MC116	NGnI[\|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFzsN5lKSzVyPUOuNVEyOTJizszN	NHuxR2xUSU6JRWK=
SCC-9	M2Tle2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M37sW2lEPTB;Mz6xNVM3PiEQvF2=	NVnRPHB5W0GQR1XS
U031	MoLCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVXmR2tZUUN3ME2zMlEzPDJ\|IN88US=>	NXvFbpFPW0GQR1XS
LCLC-103H	NYf3RVFxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MoS1TWM2OD1\|LkKzPFk1KM7:TR?=	M4LDSXNCVkeHUh?=
U-266	Mk\HS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NF7vW\|hKSzVyPUOuNlc3OzNizszN	NWO1WnZJW0GQR1XS
JVM-2	NF;yUHJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MoftTWM2OD1\|LkOyNVY1KM7:TR?=	NV3HdpRDW0GQR1XS
UACC-257	Ml7zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWDJR\|UxRTNwNE[0N\|Eh\|ryP	MmrkV2FPT0WU
LB996-RCC	M{HER2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIDOPVdKSzVyPUOuOFY2ODJizszN	NWLOcohHW0GQR1XS
BT-549	NEXNRpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MoLxTWM2OD1\|LkWwNlA6KM7:TR?=	MV\TRW5ITVJ?
NCI-H526	M4\wT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NH\hc25KSzVyPUOuOVQyPThizszN	MoDnV2FPT0WU
RH-18	NELmd\|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mn\xTWM2OD1\|Lk[xO\|k5KM7:TR?=	NUnsT21TW0GQR1XS
SW626	Ml7US5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4W4fmlEPTB;Mz63NVEzQCEQvF2=	NUXNdnhmW0GQR1XS
SK-N-AS	MkDIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGe1OIFKSzVyPUOuO\|MzPDdizszN	MW\TRW5ITVJ?
IGR-1	NG\pRXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1Tk[2lEPTB;Mz63OFI1QCEQvF2=	M330WnNCVkeHUh?=
NCI-H2291	M2PBSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWnvOoE5UUN3ME2zMlc2OzN4IN88US=>	M1TsNnNCVkeHUh?=
NCI-H441	NYiyZoZoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlrTTWM2OD1\|LkiyOFM{KM7:TR?=	NUH0dXVjW0GQR1XS
D-247MG	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYrJR\|UxRTNwOE[wN\|Eh\|ryP	NXj6dYZUW0GQR1XS
COLO-320-HSR	Ml7PS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXHTPVlIUUN3ME2zMlkyOjdzIN88US=>	MofHV2FPT0WU
A253	M3jJ[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFXOWXZKSzVyPUOuPVE1OzZizszN	MVjTRW5ITVJ?
HT55	NIm4W5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXPJR\|UxRTNwOUG3O\|Mh\|ryP	NIXYd2xUSU6JRWK=
MZ1-PC	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXnoTlFQUUN3ME2zMlk2QDZ2IN88US=>	MlHIV2FPT0WU
RERF-LC-MS	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGrYdJlKSzVyPUOuPVY2OjVizszN	MU\TRW5ITVJ?
SF268	NE\4PHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFjufJRKSzVyPUSuNVI5QDFizszN	MY\TRW5ITVJ?
RMG-I	NXnaSJBWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnjXTWM2OD12LkKxOFU1KM7:TR?=	M4i2WnNCVkeHUh?=
CFPAC-1	MkLTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mnz2TWM2OD12LkKxOlg2KM7:TR?=	M4LoXnNCVkeHUh?=
S-117	NWW0TIVvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1;2eWlEPTB;ND6yNlAzPCEQvF2=	NEXNcXhUSU6JRWK=
NCI-H2122	NYDDZYhqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXHuXmJnUUN3ME20MlMxQTNzIN88US=>	MVLTRW5ITVJ?
J82	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NELGS5BKSzVyPUSuN\|M1PDFizszN	MXrTRW5ITVJ?
CAL-72	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHTmeXhKSzVyPUSuN\|U1PzdizszN	MVjTRW5ITVJ?
GP5d	MkLiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWjJR\|UxRTRwNEGyPVgh\|ryP	NWPVd3ZsW0GQR1XS
UACC-62	M3rYbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3KzcmlEPTB;ND60OlU1PSEQvF2=	NYLMNlR6W0GQR1XS
MS-1	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2X6OmlEPTB;ND60PVEyPSEQvF2=	NV3IVYNOW0GQR1XS
RCM-1	M1fOcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mn;0TWM2OD12LkWyPVIh\|ryP	Mn7OV2FPT0WU
IST-SL1	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFXTWGlKSzVyPUSuOlU{PTlizszN	MVzTRW5ITVJ?
SW756	MoSzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M33s[GlEPTB;ND62PVE{PSEQvF2=	NFfZWWFUSU6JRWK=
HCC38	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXLJR\|UxRTRwN{GxPVch\|ryP	Ml;2V2FPT0WU
YAPC	M2\4fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NX3Tdmt5UUN3ME20MlcyOzF\|IN88US=>	MX\TRW5ITVJ?
DK-MG	M1jTcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkKzTWM2OD12Lke4NVEzKM7:TR?=	Mlu0V2FPT0WU
HCC1937	M{n0dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NX\JenVLUUN3ME20Mlg2OTJ3IN88US=>	MXvTRW5ITVJ?
OAW-28	NWDYW2JIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mo\2TWM2OD12LkmyOFM2KM7:TR?=	MkjsV2FPT0WU
MEG-01	Mn3TS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkHkTWM2OD13LkC4N\|I5KM7:TR?=	M1\jb3NCVkeHUh?=
GI-1	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWnJR\|UxRTVwMkO0PFYh\|ryP	NUTnUWZbW0GQR1XS
FADU	NGPWTGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXXJR\|UxRTVwMke4N\|ch\|ryP	M4jUeHNCVkeHUh?=
CAPAN-1	NUXnV29XT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUjtcHVbUUN3ME21MlM6PDN{IN88US=>	MnrNV2FPT0WU
TGBC11TKB	M1vHUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MoLuTWM2OD13LkS1O\|g3KM7:TR?=	M4fkWnNCVkeHUh?=
DBTRG-05MG	Mo\wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUG1fYdPUUN3ME21MlUxPTJizszN	NUPZblZPW0GQR1XS
ONS-76	NYH2W2dHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmfiTWM2OD13LkW1PFAyKM7:TR?=	NFm1Um1USU6JRWK=
Ca-Ski	NVK1foZkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NI[xWYRKSzVyPUWuOlI2PjZizszN	NWnkNo91W0GQR1XS
COLO-741	M4K3N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3zHdmlEPTB;NT63NVk6PSEQvF2=	NIrrNY1USU6JRWK=
HT-29	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NH;MT3FKSzVyPUWuPFA1PzVizszN	NEDReIJUSU6JRWK=
HCC1187	M3G0R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXjJR\|UxRTVwOEGwNFgh\|ryP	MnPzV2FPT0WU
Capan-2	M1LRdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4jSUGlEPTB;NT65OVk6PCEQvF2=	NXTMPG5HW0GQR1XS
NCI-H630	M1jNSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHHOenZKSzVyPU[uNVE1PDFizszN	M4fGbXNCVkeHUh?=
COLO-678	NEHMRWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGPwPZpKSzVyPU[uNVUxQTJizszN	NXvjbFhzW0GQR1XS
D-502MG	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MofjTWM2OD14LkG3N\|M3KM7:TR?=	MnLOV2FPT0WU
NB17	M{\rSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYPJR\|UxRTZwMkS5OFMh\|ryP	NX\BdIZJW0GQR1XS
SK-MEL-24	NFnLWXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkfnTWM2OD14LkK2OFkh\|ryP	MV;TRW5ITVJ?
NCI-SNU-5	NHruS2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{n4[mlEPTB;Nj6yO\|EyQCEQvF2=	MnqxV2FPT0WU
D-392MG	NX\sRYkxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUmybG1{UUN3ME22MlM{Ozl7IN88US=>	NU\yb3R6W0GQR1XS
A498	M1Lo[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2PFe2lEPTB;Nj60NFMxOiEQvF2=	NEKwbVhUSU6JRWK=
OCI-AML2	M1H1e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWLTeo9KUUN3ME22MlQ2PDR3IN88US=>	NFXVVnlUSU6JRWK=
HCC2157	M3\Wc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVG5cnVtUUN3ME22MlQ2PjF4IN88US=>	NUjmeG95W0GQR1XS
C3A	MoHGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGf2blBKSzVyPU[uOVIxODRizszN	MUTTRW5ITVJ?
NCI-H1650	NVzsNVZlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWXpN\|J1UUN3ME22MlcxPTJ{IN88US=>	MYnTRW5ITVJ?
DU-145	MlPJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYXHNYh6UUN3ME22Mlc4ODNizszN	MlzoV2FPT0WU
COLO-829	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWrGcFlLUUN3ME22Mlc4QDd\|IN88US=>	NIHSSHBUSU6JRWK=
LS-1034	M4fqcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MljkTWM2OD15LkC0OFEzKM7:TR?=	NGLoZm5USU6JRWK=
HCC1954	MljPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWrJR\|UxRTdwNEixN\|Qh\|ryP	MmfOV2FPT0WU
KURAMOCHI	MlrUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHfNfoNKSzVyPUeuOFg2OzNizszN	MonBV2FPT0WU
Mo-T	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4XnemlEPTB;Nz61NVQ6QCEQvF2=	M1HrfXNCVkeHUh?=
OE19	MlzTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MorvTWM2OD15Lk[1OVA{KM7:TR?=	NV3tW2dQW0GQR1XS
COR-L105	M3rVZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXG0PFY{UUN3ME23MlcyPDJzIN88US=>	MlrVV2FPT0WU
NCI-H2342	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUfJR\|UxRTdwN{G1NlEh\|ryP	MorpV2FPT0WU
U-87-MG	NGrG[IFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWPXNGxLUUN3ME24MlA{OzN2IN88US=>	NWPmS4FsW0GQR1XS
MKN28	NXzocGoyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NF\yNY1KSzVyPUiuNVE2OTVizszN	M3WxTXNCVkeHUh?=
HT-1197	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MkjmTWM2OD16LkK1PVA4KM7:TR?=	M2LvVXNCVkeHUh?=
ChaGo-K-1	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MknETWM2OD16LkO0NlQ2KM7:TR?=	MXnTRW5ITVJ?
NCI-H226	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWLiPZRTUUN3ME24MlQ1OzNzIN88US=>	MWDTRW5ITVJ?
NCI-H2029	MoDrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIrDVXJKSzVyPUmuNFY4PTlizszN	NVzURXpXW0GQR1XS
TE-11	M2\Ncmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYTJR\|UxRTlwNEW1PFgh\|ryP	NX\BR45qW0GQR1XS
ZR-75-30	NVjS[WJYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHS4TW1KSzVyPUmuPVI3OzRizszN	MXnTRW5ITVJ?
SW837	NILVOphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYHJR\|UxRTFyLkKyPVMh\|ryP	MVnTRW5ITVJ?
NCI-H1651	NYXhOZJiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFLjUnFKSzVyPUGwMlI{OjZizszN	MnXyV2FPT0WU
NCI-H727	MkXjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2LDU2lEPTB;MUCuOFQ6PSEQvF2=	MUnTRW5ITVJ?
NCI-H358	Ml3tS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1j0cWlEPTB;MUCuPFM3PSEQvF2=	MkPlV2FPT0WU
NCI-H2087	M4\1UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mlz0TWM2OD1zMT6wOFM1KM7:TR?=	MUnTRW5ITVJ?
FTC-133	NU\BcmhLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFLlSIlKSzVyPUGxMlQxPTFizszN	MYXTRW5ITVJ?
LAN-6	M3XBd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MomwTWM2OD1zMj6xNlQh\|ryP	M3rDRXNCVkeHUh?=
NCI-H1838	M3PBOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHfJUJFKSzVyPUGyMlUyPTFizszN	MXvTRW5ITVJ?
Calu-6	NYfTdZJkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4HOVWlEPTB;MUSuNVAzOSEQvF2=	NFvqUFNUSU6JRWK=
HCC70	M3n1cWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUjJR\|UxRTF2LkS1NUDPxE1?	NUnV[3piW0GQR1XS
KARPAS-299	MoTOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWTJR\|UxRTF3LkKxOVkh\|ryP	NVvPbVFZW0GQR1XS
CAL-27	NXrjXlJbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MoHHTWM2OD1zNT6zPFQ{KM7:TR?=	NFzkV4pUSU6JRWK=
NCI-H82	M{j3[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmnvTWM2OD1zNT61N\|Ih\|ryP	MUjTRW5ITVJ?
no-10	NFPrRYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYnJR\|UxRTF3LkmzPEDPxE1?	NGHuWnZUSU6JRWK=
U251	M4L2Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVj2TnNZUUN3ME2xOk4{Pjd3IN88US=>	MWPTRW5ITVJ?
TE-9	Ml;FS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3;CfGlEPTB;MUeuOVE3PiEQvF2=	M4\5SnNCVkeHUh?=
TE-10	M37GVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWnsToJwUUN3ME2xPU4xPjB5IN88US=>	NHjPWW5USU6JRWK=
COLO-824	NF25NGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHT4eHdKSzVyPUKwMlkzPzZizszN	MknEV2FPT0WU
HuP-T3	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVjJR\|UxRTJzLkC3OFgh\|ryP	NHvpO\|ZUSU6JRWK=
KALS-1	NV[1dpZRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYPJR\|UxRTJzLkG3OUDPxE1?	NGfQWpdUSU6JRWK=
L-428	MkOxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHzKcnZKSzVyPUKxMlQxOTZizszN	NGC2SXhUSU6JRWK=
JAR	M{\Y[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NX23PGtiUUN3ME2yNU42ODJizszN	MnnCV2FPT0WU
DoTc2-4510	MorjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWrJR\|UxRTJ\|Lki0O\|Uh\|ryP	MX7TRW5ITVJ?
ABC-1	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MorVTWM2OD1{Nj63PVU4KM7:TR?=	NFTpOYJUSU6JRWK=
MHH-NB-11	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MkKyTWM2OD1\|Mz6zOFY1KM7:TR?=	M{PjW3NCVkeHUh?=
SW1463	M1fubWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3\QN2lEPTB;M{OuPVg{KM7:TR?=	NXHuWo5FW0GQR1XS
SW1417	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NX\KOHpOUUN3ME2zO{4xQTV{IN88US=>	M2TqR3NCVkeHUh?=
NB12	NX7QNIY4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2mwV2lEPTB;M{muOFY2PSEQvF2=	NIXEfphUSU6JRWK=
NY	NGL4cHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlnzTWM2OD12MT6zNlAyKM7:TR?=	M{PmS3NCVkeHUh?=
H1048	NHH4[5BCeG:ydH;zbZMhSXO\|YYm=	NV3XW\|JGPTByIH7N	Mn3CO\|IhcA>?		NHvJZpBvcGGwY3XzJGFDXC1{NkRihLNqdmS3Y3XkJIFxd3C2b4Ppdy=>	M{fSN\|I2PzN5NUSy
H86	MlvCRZBweHSxc3nzJGF{e2G7	MVm1NFAhdk1?	NYXqeIp3PzJiaB?=		NHjldWVvcGGwY3XzJGFDXC1{NkRihLNqdmS3Y3XkJIFxd3C2b4Ppdy=>	MYmyOVc{PzV2Mh?=
H196	MXXBdI9xfG:\|aYOgRZN{[Xl?	NVm4e297PTByIH7N	MmfOO\|IhcA>?		MnPIcohidmOnczDBRnQuOjZ\|4pETbY5lfWOnZDDhdI9xfG:\|aYO=	MViyOVc{PzV2Mh?=
H446	MlrCRZBweHSxc3nzJGF{e2G7	NYPBVnlPPTByIH7N	MnTNO\|IhcA>?		NYDPeGRzdmijbnPld{BCSlRvMk[z5qCUcW6mdXPl[EBieG:ydH;zbZM>	MVeyOVc{PzV2Mh?=
TFK-1	MnTjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NWj5Tlh4PzJiaB?=	M1HDd2ROW09?	MoTvTWM2OD12NzDuUS=>	Ml;kNlUyPTJ{NES=
EGI-1	NWPPPXBJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MlLQO\|IhcA>?	MYfEUXNQ	NYrRR3FRUUN3ME21N{BvVQ>?	MnjTNlUyPTJ{NES=
OCI/AML3	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1W1PVAvOiEQvF2=	M17DXlQ5KGh?		NEDWb2tmdmijbnPld{Bk\WyuIHfyc5d1cCCrbnjpZol1cW:wIHnu[JVk\WRiYomgd4VtfW2ndHnubYI>	NYXsVXc2OjR5M{mzPVM>
U937	NX:4cVV7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkHoNE4zKM7:TR?=	M4\FSVQ5KGh?		MkPk[Y5p[W6lZYOgZ4VtdCCpcn;3eIghcW6qaXLpeIlwdiCrbnT1Z4VlKGK7IIPlcJVu\XSrbnni	MYKyOFc{QTN7Mx?=
MOLM13	NE\YbFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVrsPXdtOC5{IN88US=>	M3XqPFQ5KGh?		NHHEPG5mdmijbnPld{Bk\WyuIHfyc5d1cCCrbnjpZol1cW:wIHnu[JVk\WRiYomgd4VtfW2ndHnubYI>	NFPkdoQzPDd\|OUO5Ny=>
MCF7	MkPtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MY[yNEBvVQ>?	MlnsO\|IhcA>?	Ml33SmJU	NHTkeVRz\WS3Y3XzJJRp\SCSRVzQNU1u\WSrYYTl[EBqdmO{ZXHz[UBqdiClZXzsJJZq[WKrbHn0fS=>	NFXOSXgzPDZ6OEC0Oi=>
TamR	NYHDfo5XT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MofKTWM2OD1zOPMAjY5O	M1[0c\|I1PDV5ME[5
MCF7-X	NGD1PIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NF\ZeYFKSzVyPUK0JI5O	M3nF[FI1PDV5ME[5
T47D-tamR	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXHJR\|UxRTF7IH7N	NEPOPFIzPDR3N{C2PS=>
293T	MWTGeY5kfGmxbjDBd5NigQ>?	M1:xfVIxKG6P	NWPvdZFJOyCq		MlTP[Il{enWydIOgRYt1NW2nZHnheIVlKFSLRj3JRUB{fGGkaXzpeJktKHS{YX7zcI9k[XSrb36sJIFv\CCjY4Tpeol1gQ>?	M1rKVFI1OzZ\|NES5
SW620	MoTUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3;5R\|AvODBzLUGw{txO	MX[yOEBp		NIWzcIxqdmirYnn0d{B1cGViY3XscEBxem:uaX\ldoF1cW:wIHHzJJRp\SClb37j[Y51emG2aX;uJJJqe2W\|	M4rkU\|I1OzZ\|NES5
Huh7	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUL4TpZNPS1zMECgcm0>	Mmr2NE0zPCCq	NWP5[FE6TE2VTx?=	MXHpcoNz\WG\|ZYOgZ4VtdCCmZXH0bEBqdiCjIHPvcoNmdnS{YYTpc44uKGGwZDD0bY1mNWSncHXu[IVvfCCvYX7u[ZI>	M4DMS\|I1Ojl5M{Cw
Hep3B	NIjzcXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUfMPVF6PS1zMECgcm0>	NYeyWoNbOC1{NDDo	M2TkfmROW09?	NEPYSm9qdmO{ZXHz[ZMh[2WubDDk[YF1cCCrbjDhJINwdmOnboTyZZRqd25vIHHu[EB1cW2nLXTldIVv\GWwdDDtZY5v\XJ?	NYjuTWdFOjR{OUezNFA>
Huh7	MlrHSpVv[3Srb36gRZN{[Xl?	MlH4NVAxKG6P	M{TxNVEzKGh?	MoDVSG1UVw>?	NYrRdFhwcW6mdXPld{BifXSxcHjh[5nDqA>?	M3rx[\|I1Ojl5M{Cw
U87-MG	MojBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MXu3NkBp		M{\XRmdKPTEkgJm95qCKPzlibl5CpC=>	MkjjNlQzPDl4NEC=
L3.6pl	NYrTfIxoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXXxTo1kOSEQvF2=	NFnLSmQ4OiCq		M3HafolvcGmkaYTzJJRp\SClZXzsJIdzd3e2aDDjc41jcW6nZDD3bZRpKEKPUz23O\|c3ODd?	NH7qfnYzPDJ\|M{O5PS=>
TE671	MkfnRZBweHSxc3nzJGF{e2G7	NWLRW4N1OSEQvF2=	NUK5e2pEPDhiaB?=		M3TmfIlv[3KnYYPld{Bk\WyuIHHwc5B1d3OrczDpcoR2[2WmIHL5JGFDXC15M{e=	NUjhSGdJOjRzM{OyNVg>
RD	NYS1eHZDSXCxcITvd4l{KEG\|c3H5	MoqzNUDPxE1?	MkjlOFghcA>?		MVTpcoNz\WG\|ZYOgZ4VtdCCjcH;weI9{cXNiaX7keYNm\CCkeTDBRnQuPzN5	NFfiWVYzPDF\|M{KxPC=>
RMS13	NHzEfWVCeG:ydH;zbZMhSXO\|YYm=	NEHhblgyKM7:TR?=	NUHUUZdYPDhiaB?=		NYfBNJFOcW6lcnXhd4V{KGOnbHygZZBweHSxc3nzJIlv\HWlZXSgZpkhSUKWLUezOy=>	MnjVNlQyOzN{MUi=
RH30	NVHSSnFiSXCxcITvd4l{KEG\|c3H5	M{TONVEh\|ryP	M{HIblQ5KGh?		NFvT[JZqdmO{ZXHz[ZMh[2WubDDhdI9xfG:\|aYOgbY5lfWOnZDDifUBCSlRvN{O3	MlTCNlQyOzN{MUi=
Hep-2	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkTrNE4xOS1zIN88US=>	NEHaelUyOi17NjDo		MkLJbY5kemWjc3XzJINmdGxiZHXheIghcW5iYTDjc45k\W62cnH0bY9vNSCjbnSgeIlu\S2mZYDlcoRmdnRibXHucoVz	M4O4SFI1OTB\|N{S5
SCC-9	M3zRSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYTpXlBCOC5yMT2xJO69VQ>?	NFLYOZYyOi17NjDo		M1TpeIlv[3KnYYPld{Bk\WyuIHTlZZRpKGmwIHGgZ49v[2WwdILheIlwdi1iYX7kJJRqdWVvZHXw[Y5l\W62IH3hco5meg>?	MmqwNlQyODN5NEm=
Hep-2	MlWySpVv[3Srb36gRZN{[Xl?	MVWwMlEwOC53IN88US=>	MkXzNlQhcA>?		NVfOT3JZ[myxY3vzJI1VV1KFMTDhcoQhdVSRUlOyJIFkfGm4YYTpc44>	NFvTRVQzPDFyM{e0PS=>
SCC-9	NFqzVHJHfW6ldHnvckBCe3OjeR?=	MorvNE4yNzBwNTFOwG0>	MoW4NlQhcA>?		MXXicI9kc3NibWTPVmMyKGGwZDDtWG9TSzJiYXP0bZZifGmxbh?=	MkOxNlQyODN5NEm=
PANC-1	NYfyXVRNSXCxcITvd4l{KEG\|c3H5	M2\kOVUxOCCwTR?=	NWju[pNkPDhiaB?=		NHjKT4F{\W6\|aYTpfoV{KHCjbnPy[YF1cWNiY3HuZ4VzKGOnbHzzJJRwKHKjZHnveIhmemGyeR?=	MnfhNlM5QDZ{OUS=
RMG2	MlezRZBweHSxc3nzJGF{e2G7	NEX2e3UyNTFyMECgcm0>	M13KbVczKGh?	MlzFSmJU	NYjGOXJ7cW6qaXLpeJMhfGinIHPlcIwhfmmjYnnsbZR6KGOxbnPlcpRz[XSrb36g[IVx\W6mZX70cJk>	NFnvWXkzOzZzNU[zNS=>
HAC2	M2rOeWFxd3C2b4Ppd{BCe3OjeR?=	MWCxMVExODBibl2=	Mn3jO\|IhcA>?	M1LqeWZDWw>?	M1qxU4lvcGmkaYTzJJRp\SClZXzsJJZq[WKrbHn0fUBkd26lZX70doF1cW:wIHTldIVv\GWwdHz5	MWSyN\|YyPTZ\|MR?=
HT-29	NWr1ZW16SXCxcITvd4l{KEG\|c3H5	NXT4UG1jOSEQvF2=	M{LV[lczKGh?		MlfiZZR1\W63YYTld{A2NU[XLXnu[JVk\WRiY3XscEBl\WG2aB?=	M4PTU\|IyQTR7MUKx
DLD1	NHXQNI9CeG:ydH;zbZMhSXO\|YYm=	MmDWNUDPxE1?	MonwO\|IhcA>?		MlGxZZR1\W63YYTld{A2NU[XLXnu[JVk\WRiY3XscEBl\WG2aB?=	MmftNlE6PDlzMkG=
HT-29	NIHIeVhHfW6ldHnvckBCe3OjeR?=	NFLoUIMyKM7:TR?=	NIfVV2k4OiCq		M17DTolv\HWlZYOgZZV1d3CqYXf5JJRwKGOxbn\ldkBkgXSxcILveIVkfGmxbh?=	MYmyNVk1QTF{MR?=
DLD1	M1L6U2Z2dmO2aX;uJGF{e2G7	MlXhNUDPxE1?	MljsO\|IhcA>?		NImzeVRqdmS3Y3XzJIF2fG:yaHHnfUB1dyClb37m[ZIh[3m2b4Dyc5Rm[3Srb36=	MlHENlE6PDlzMkG=
Rh41	NIrtR4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MoDHTWM2OD1\|MD63JI5O	MoTQNlE{Ozd4N{m=
Rh18	NFf3blFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{LGcGlEPTB;NEGuOEBvVQ>?	NVHtOnE1OjF\|M{e2O\|k>
Rh30	NYjsephVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4DE[mlEPTB;MUSgcm0>	M2rCV\|IyOzN5Nke5
BT-12	MlfXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkDsTWM2OD1{ND63JI5O	Ml3SNlE{Ozd4N{m=
CHLA-266	Mn7jS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmL5TWM2OD1zLkGgcm0>	MonyNlE{Ozd4N{m=
TC-71	NGDmcHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWTrT2tCUUN3ME20Ok42KG6P	MnvKNlE{Ozd4N{m=
CHLA-9	MoPwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NEPDXnVKSzVyPUG1MlMhdk1?	Mnf4NlE{Ozd4N{m=
CHLA-10	MoHIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4jsdGlEPTB;Mz65JI5O	NHnBUFEzOTN\|N{[3PS=>
CHLA-258	NEHSWYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXfJR\|UxRTFyLkSgcm0>	NWS4TI9bOjF\|M{e2O\|k>
GBM2	NGH4SmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWrJR\|UxRTRyLkegcm0>	MWSyNVM{PzZ5OR?=
NB-1643	M3zoNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1PSRWlEPTB;M{OuPEBvVQ>?	Mn;nNlE{Ozd4N{m=
NB-EBc1	Mn65S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MX7JR\|UxRTJ5LkGgcm0>	M4TzUlIyOzN5Nke5
CHLA-90	M{\Ibmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MX;JR\|UxRTN2LkWgcm0>	MUeyNVM{PzZ5OR?=
CHLA-136	MmHnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVHJR\|UxRTF4Mj62JI5O	MlXlNlE{Ozd4N{m=
NALM-6	M1\kb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYjHXnVnUUN3ME2zNk46KG6P	M{niTlIyOzN5Nke5
COG-LL-317	M2LUWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGfTNoRKSzVyPUGuN{BvVQ>?	M4DFNVIyOzN5Nke5
RS4;11	NU\4bGxGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWS3XnZTUUN3ME2zOUBvVQ>?	NHLIb\|MzOTN\|N{[3PS=>
MOLT-4	MlvoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIHROWZKSzVyPUiuOkBvVQ>?	MXSyNVM{PzZ5OR?=
CCRF-CEM	NXXVb4x5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkfuTWM2OD12LkGgcm0>	M1u5[FIyOzN5Nke5
Kasumi-1	NGTqfnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHvvdnlKSzVyPUGuOEBvVQ>?	NVvrV4ZnOjF\|M{e2O\|k>
Karpas-299	NYHIZ4RWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGftNW9KSzVyPUKxMlchdk1?	NFLhXVUzOTN\|N{[3PS=>
Ramos-RA1	NGPWOlRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4rFSmlEPTB;OD6yJI5O	NFjCdHgzOTN\|N{[3PS=>
H838	NVviW5VxTnWwY4Tpc44hSXO\|YYm=	NF6zNFgyKM7:TR?=	NXj4PXFnPDhiaB?=		NGrib5RqdmS3Y3XzJINmdGxiYYX0c5Bp[We7	MlXlNlA{PjRzMUO=
H838	NWLMcppsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUnLdlA4OC1\|IN88US=>	MVu3NkBp		NGrDe5FqdmS3Y3XzJIdzd3e2aDDpcohq[mm2aX;uJIFv\CCjdYTvdIhi\3l?	M3v6c\|IxODJ6OEW0
A549	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MX6wMVMh\|ryP	M335flczKGh?		M1vDbIlv\HWlZYOg[5Jwf3SqIHnubIljcXSrb36gZY5lKGG3dH;wbIFogQ>?	NF7vcYQzODB{OEi1OC=>

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	p-mTOR / p-AKT / p-4EBP1 / p-P70S6K / p-PRAS40; PubMed: 24457069 Breast Cancer Res Western blots of 70% confluent TamR (A) and MCF7-X (B) cells treated for 15 minutes to 24 hours with AZD8055 (0 to 100 nM). Blots were probed with phospho- and total antibodies for mTORC1 and two signalling pathways. In both cell lines mTORC1 and mTORC2 s䲧疝Ỵ疞㧀疜膉痘 瘿삨ՂᾰƌՂĀ 㺣痖帉痖Ѐ瑖堘𢡄빢᎒ՂĀ鑸᎒彿堙奋堙巫堙᎒ﻺ᎒彿堙ﻮ᎒塚堙ﻺ᎒ꍈ堞빢᎒學堙漸堞圔堙빢᎒圞堙 p-EGFR / EGFR; PubMed: 25654224 Int J Mol Sci PANC-1 cells were treated with AZD8055 for the indicated hours and EGFR (T/P), AKT (T/P) and ribosomal protein S6 (S6) (T/P) proteins were examined by western-blot; p-FOXO1 / FOXO1 / p-FOXO3a / FOXO3a ; PubMed: 25654224 Int J Mol Sci PANC-1 cells were transfected with FoxO1/FoxO3a siRNAs and treated with AZD8055 for 1 h, then AKT (T/P), FoxO1 (T/P), FoxO3a (T/P) and EGFR (T/P) proteins were examined by western-blot.	24457069 25654224
Immunofluorescence	p-4EBP1 / EIF4E / mTOR; PubMed: 24600487 Int J Clin Exp Med (C) Hoechst 33258 staining of Hep-2 cells after treatment with AZD8055 for 24 hours were shown. The cells were fixed and immunereacted with anti-mTOR antibody followed by incubation with Alexa 488-labeled secondary antibody (C-F). Images were taken by a c䲧疝Ỵ疞㧀疜膉痘 瘿삨ՂᾰƌՂĀ 㺣痖帉痖Ѐ瑖堘𢡄빢᎒ՂĀ鑸᎒彿堙奋堙巫堙᎒ﻺ᎒彿堙ﻮ᎒塚堙ﻺ᎒ꍈ堞빢᎒學堙漸堞圔堙빢᎒圞堙圭堙𢡄玚Wᾰƌ ᾰƌ戤瘯Ɖ�෋䐺痖暼瘿�෋ᾰƌ �෋à㺣痖�෋𢡄�෋䀷痗�෋౴�෋㵶痗�෋뺖᎒泌Itemｾ᎒Count﫨呂�෋猴፲�෋፲씢痗猸፲髸莤䥷堙᎒ｾ᎒�堞ﻮ᎒፲露𢡄堚،齃礤v�堞ﻮ᎒猢Wｾ᎒䨼Ą鹿齃殺獸W戀醙玛W戀ⶰ໯齃礤v 玚W玢Wⶰ໯﫰礌vtЉᔈැ鲬౴᥊疜犈፲Eo狜፲艘ᎂ艘ᎂ⩈̎䥠̌씢痗狠፲붖᎒i變ﱘ﫰﬐먙堘붖᎒狠፲i變ﱘ﫰먰堘ﱘ붖᎒�堞봆᎒릎堘붖᎒i꣩쯟巰痗ꣵ쯟巰痗Љ镴౴嶴痗Љ镨౴ᔈැ竗ᔈැ屷痗W竗尊痗 LC3B / p62 ; PubMed: 30337536 Cell Death Dis Immunofluorescence staining of U87 and U251 GICs, which treated by DMSO, AZD8055 (0.3 μM) and rapamycin (3 μM). The nuclei were stained with DAPI and the antibody against LC3B and p62. Images were captured by laser confocal microscope ( × 400), scale bar 䲧疝Ỵ疞	24600487 30337536
Growth inhibition assay	Cell viability ; PubMed: 29263324 Nat Commun Growth for the indicated cell lines was assessed after 72 h of treatment with AZD8055 (0–250 nM). Results are expressed as a percentage of cell number relative to the DMSO-treated control cells a.	29263324

In vivo

AZD8055 inhibits the pS6 and pAkt in U87MG and A549 xenografts at 2.5/10 mg/kg, which leads to tumor growth inhibition. AZD8055 shows significant antitumor activity in many xenografts, including U87MG, BT474c, A549, Calu-3, LoVo, SW620, PC3 and MES-SA at a dose of 10/20 mg/kg. ^[1] AZD8055 induces ~40% reduction in tumour volume, accompanied by ablation of phosphorylation of Akt, S6K and SGK protein kinases. Administration of AZD8055 (5mg/kg, Bid) and SAHA (100 mg/kg/d) results in complete tumor growth inhibition in PTEN+/−LKB1+/hypo xenografts without side effects on mice by inhibition of mTORC1 and mTORC2 signaling. ^[4]

Protocol

Kinase Assay:^[1]	- Collapse Cell-based determinations of mTOR inhibition: A high-throughput screening cell-based assay is developed using MDA-MB-468 cells to detect mTORC1 and mTORC2 activity. Cells are exposed for 2 hours to increasing concentrations of AZD8055. At the end of the incubation period, cells are fixed, washed, and probed with antibodies against S473 pAkt or against S235/236 phosphorylated S6 (pS6). Levels of phosphorylation are assessed using an Acumen laser scanning cytometer.
Cell Research:^[1]	- Collapse Cell lines: U87MG, A549 and H838 cells Concentrations: 1 nM - 1 μM Incubation Time: 72 to 96 hours Method: Cells are exposed to AZD8055 for 72 to 96 hours and stained for cell nuclei (0.03 mg/mL Hoechst 33342) and acidic vesicles (1 μg/mL acridine orange). Images are captured at 450 and 536 nm on an ArrayScan II platform, and the percentage of acidic vesicles and the number of cells are quantified. For LC3 assessment, cells are exposed to e64d/pepstatin (10 μg/mL) for 30 to 90 min before incubation with AZD8055. Cells are lysed on ice and analyzed by immunoblotting. (Only for Reference)
Animal Research:^[1]	- Collapse Animal Models: U87MG, BT474c, A549, Calu-3, LoVo, SW620, PC3 and MES-SA U87-MG and A549 are established in pathogen-free, female nude mice (nu/nu:Alpk). Dosages: 2.5-20 mg/kg Administration: Oral gavage once or twice daily (Only for Reference)

References

[4] García-Martínez JM, et al. Br J Cancer, 2011, 104(7), 1116-1

- Collapse

Solubility (25°C)

In vitro	DMSO	50 mg/mL warmed (107.4 mM)
	Water	Insoluble
	Ethanol	'3 mg/mL
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 4% DMSO+30% PEG 300+ddH2O For best results, use promptly after mixing.	5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download AZD8055 SDF

Molecular Weight	465.54
Formula	C₂₅H₃₁N₅O₄
CAS No.	1009298-09-2
Storage	3 years-20°C powder 2 years-80°C in solvent
Synonyms	N/A
Smiles	CC1COCCN1C2=NC(=NC3=C2C=CC(=N3)C4=CC(=C(C=C4)OC)CO)N5CCOCC5C

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage

mg/kg

Average weight of animals

Dosing volume per animal

Number of animals

Step 2: Enter the in vivo formulation (Different batches have different solubility ratios, please contact Selleck to provide you with the correct ratio)

% DMSO+ % + % Tween 80+ % ddH₂O

Calculate Reset

Calculation results:

Working concentration： mg/ml；

Method for preparing DMSO master liquid: ： mg drug pre-dissolved in μL DMSO (Master liquid concentration mg/mL， Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation：Take DMSO master liquid, next addμL PEG300， mix and clarify, next addμL Tween 80，mix and clarify, next add μL ddH₂O，mix and clarify.

Note：1.Please make sure the liquid is clear before adding the next solvent.
2.Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

mTOR Signaling Pathway Map

mTOR Inhibitors with Unique Features

Selective mTOR inhibitor

Rapamycin (Sirolimus) : mTORC1-selective, IC50=~0.1 nM.
Most Potent mTOR Inhibitor

Rapamycin (Sirolimus) : mTOR, IC50=~0.1 nM.
FDA-approved mTOR Inhibitor

Temsirolimus (CCI-779, NSC 683864) : Approved by FDA for Renal Cell Carcinoma (RCC).
Newest mTOR Inhibitor

XL388 ^New : Highly potent, selective, ATP-competitive inhibitor of mTOR with IC50 of 9.9 nM, 1000-fold selectivity over the closely related PI3K kinases.

Related mTOR Products

MHY1485 ^New

MHY1485 is a potent, and cell-permeable mTOR activator, and also potently inhibits autophagy.
CHIR-99021 (CT99021) ^New

CHIR-99021 (CT99021) is a GSK-3α and GSK-3β inhibitor with IC50 of 10 nM and 6.7 nM, respectively. CHIR99201 does not exhibit cross-reactivity against cyclin-dependent kinases (CDKs) and shows a 350-fold selectivity toward GSK-3β compared to CDKs. CHIR99021 functions as a Wnt/β-catenin activator and induces autophagy.
Dorsomorphin (Compound C) ^New

Dorsomorphin is a potent, reversible, selective AMPK inhibitor with K_i of 109 nM in cell-free assays, exhibiting no significant inhibition of several structurally related kinases including ZAPK, SYK, PKCθ, PKA, and JAK3. Dorsomorphin selectively inhibits the BMP type I receptors ALK2, ALK3 and ALK6. Dorsomorphin is used in promoting specific cell differentiation and inducing cancer cell line autophagy.
Rapamycin (Sirolimus)

Rapamycin (Sirolimus, AY 22989, NSC-2260804) is a specific mTOR inhibitor with IC50 of ~0.1 nM HEK293 cells.
Everolimus (RAD001)

Everolimus (RAD001) is an mTOR inhibitor of FKBP12 with IC50 of 1.6-2.4 nM in a cell-free assay. Everolimus induces cell apoptosis and autophagy and inhibits tumor cells proliferation.
Torin 1

Torin 1 is a potent inhibitor of mTORC1/2 with IC50 of 2 nM/10 nM in cell-free assays; exhibits 1000-fold selectivity for mTOR than PI3K.
Temsirolimus (CCI-779)

Temsirolimus (CCI-779, NSC 683864) is a specific mTOR inhibitor with IC50 of 1.76 μM in a cell-free assay. Temsirolimus induces autophagy and apoptosis.
Sapanisertib (MLN0128)

Sapanisertib (MLN0128, INK 128, TAK-228) is a potent and selective mTOR inhibitor with IC50 of 1 nM in cell-free assays; >200-fold less potent to class I PI3K isoforms, superior in blocking mTORC1/2 and sensitive to pro-invasion genes (vs Rapamycin). Phase 1.
Tacrolimus (FK506)

Tacrolimus (FK506, FR900506, Fujimycin, Prograf) is a 23-membered macrolide lactone, it reduces peptidyl-prolyl isomerase activity in T cells by binding to the immunophilin FKBP12 (FK506 binding protein) creating a new complex. Tacrolimus also inhibits the phosphatase activity of calcineurin. Tacrolimus induces vascular endothelial autophagy.
KU-0063794

KU-0063794 is a potent and highly specific dual-mTOR inhibitor of mTORC1 and mTORC2 with IC50 of ~10 nM in cell-free assays; no effect on PI3Ks.

Choose Your Country or Region

By Signaling Pathways

By product type

AZD8055